

# Dimitri P Mikhailidis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6972626/publications.pdf>

Version: 2024-02-01

929  
papers

33,163  
citations

4641

85  
h-index

11581

135  
g-index

942  
all docs

942  
docs citations

942  
times ranked

31604  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mean Platelet Volume: A Link Between Thrombosis and Inflammation?. <i>Current Pharmaceutical Design</i> , 2011, 17, 47-58.	0.9	990
2	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet</i> , The, 2010, 376, 1916-1922.	6.3	594
3	The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. <i>Atherosclerosis</i> , 2015, 241, 507-532.	0.4	587
4	The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2692-2701.	1.8	518
5	Non-alcoholic fatty liver disease and dyslipidemia: An update. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1109-1123.	1.5	363
6	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.4	311
7	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , 2017, 75, 307-326.	2.6	294
8	Orlistat-Associated Adverse Effects and Drug Interactions. <i>Drug Safety</i> , 2008, 31, 53-65.	1.4	289
9	The Relation Between Atherosclerosis and the Neutrophil-Lymphocyte Ratio. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 405-411.	0.7	271
10	Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2011, 9, 258-270.	0.8	265
11	Platelets as Predictors of Vascular Risk: Is There a Practical Index of Platelet Activity?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 177-190.	0.7	253
12	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006, 22, 873-883.	0.9	238
13	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	2.6	238
14	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 1293-1301.	1.5	236
15	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. <i>American Journal of Kidney Diseases</i> , 2004, 43, 589-599.	2.1	224
16	Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study. <i>Journal of Psychosomatic Research</i> , 2010, 69, 179-185.	1.2	217
17	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216
18	Elevated heart rate and atherosclerosis: An overview of the pathogenetic mechanisms. <i>International Journal of Cardiology</i> , 2008, 126, 302-312.	0.8	208

#	ARTICLE	IF	CITATIONS
19	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017, 71, 17-32.	1.5	208
20	Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	207
21	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.4	206
22	Leptin, cardiovascular diseases and type 2 diabetes mellitus. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1176-1188.	2.8	197
23	&#x201C;European Panel on Low Density Lipoprotein (LDL) Subclasses&#x201D;: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. <i>Current Vascular Pharmacology</i> , 2011, 9, 533-571.	0.8	187
24	Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. <i>Progress in Lipid Research</i> , 2012, 51, 314-324.	5.3	187
25	The Prevalence of Metabolic Syndrome in Various Populations. <i>American Journal of the Medical Sciences</i> , 2007, 333, 362-371.	0.4	181
26	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , 2008, 23, 370-378.	0.8	180
27	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	2.3	169
28	The role of Toll-like receptors in renal diseases. <i>Nature Reviews Nephrology</i> , 2010, 6, 224-235.	4.1	168
29	Effects of Coenzyme Q10 on Statin-Induced Myopathy. <i>Mayo Clinic Proceedings</i> , 2015, 90, 24-34.	1.4	168
30	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. <i>Current Medical Research and Opinion</i> , 2005, 21, 1157-1159.	0.9	165
31	The effect of smoking on arterial stiffness. <i>Hypertension Research</i> , 2010, 33, 398-410.	1.5	163
32	Early vascular benefits of statin therapy. <i>Current Medical Research and Opinion</i> , 2003, 19, 540-556.	0.9	159
33	Endocan: A novel inflammatory indicator in cardiovascular disease?. <i>Atherosclerosis</i> , 2015, 243, 339-343.	0.4	159
34	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 118-127.	0.4	158
35	Lipid-modifying effects of nutraceuticals: An evidence-based approach. <i>Nutrition</i> , 2016, 32, 1179-1192.	1.1	157
36	Analysis of vitamin D levels in patients with and without statin-associated myalgia â€” A systematic review and meta-analysis of 7 studies with 2420 patients. <i>International Journal of Cardiology</i> , 2015, 178, 111-116.	0.8	154

#	ARTICLE	IF	CITATIONS
37	Prevalence of statin intolerance: a meta-analysis. <i>European Heart Journal</i> , 2022, 43, 3213-3223.	1.0	151
38	A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. <i>Cardiovascular Research</i> , 2002, 54, 528-538.	1.8	148
39	Statin therapy and plasma coenzyme Q10 concentrations – A systematic review and meta-analysis of placebo-controlled trials. <i>Pharmacological Research</i> , 2015, 99, 329-336.	3.1	145
40	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	0.9	144
41	Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. <i>Atherosclerosis</i> , 2016, 253, 194-208.	0.4	142
42	Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. <i>Atherosclerosis</i> , 2015, 241, 433-442.	0.4	139
43	Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors – Results from a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2015, 189, 47-55.	0.8	138
44	The impact of statin therapy on plasma levels of von Willebrand factor antigen. <i>Thrombosis and Haemostasis</i> , 2016, 115, 520-532.	1.8	138
45	Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. <i>Rheumatology International</i> , 2011, 31, 153-164.	1.5	134
46	Association of Drinking Pattern and Alcohol Beverage Type With the Prevalence of Metabolic Syndrome, Diabetes, Coronary Heart Disease, Stroke, and Peripheral Arterial Disease in a Mediterranean Cohort. <i>Angiology</i> , 2007, 58, 689-697.	0.8	133
47	Endocan – A Novel Inflammatory Indicator in Newly Diagnosed Patients With Hypertension. <i>Angiology</i> , 2014, 65, 773-777.	0.8	133
48	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. <i>Scientific Reports</i> , 2015, 5, 9902.	1.6	133
49	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , 2015, 21, 7860.	1.4	130
50	Drug-induced fibrotic valvular heart disease. <i>Lancet, The</i> , 2009, 374, 577-585.	6.3	129
51	Adiponectin, lipids and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2017, 28, 347-354.	1.2	129
52	Arterial Stiffness in the Heart Disease of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 918-928.	3.0	128
53	Association between statin use and plasma D-dimer levels. <i>Thrombosis and Haemostasis</i> , 2015, 114, 546-557.	1.8	127
54	Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 153-163.	0.6	126

#	ARTICLE	IF	CITATIONS
55	Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. <i>Nutrients</i> , 2013, 5, 928-948.	1.7	124
56	Influence of Smoking on Predictors of Vascular Disease. <i>Angiology</i> , 2003, 54, 507-530.	0.8	123
57	Ghrelin Can Bind to a Species of High Density Lipoprotein Associated with Paraoxonase. <i>Journal of Biological Chemistry</i> , 2003, 278, 8877-8880.	1.6	123
58	Cyclosporine A enhances platelet aggregation. <i>Kidney International</i> , 1987, 32, 889-895.	2.6	120
59	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2011, 31, 730-739.	1.9	120
60	Serum endocan levels as a marker of disease activity in patients with Behçet disease. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 291-296.	0.6	120
61	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , 2015, 21, 6820-6834.	1.4	120
62	Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. <i>Circulation Journal</i> , 2007, 71, 1120-1127.	0.7	119
63	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	1.0	117
64	Clinical Relevance of Postprandial Lipaemia. <i>Current Medicinal Chemistry</i> , 2005, 12, 1931-1945.	1.2	115
65	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 509-515.	0.9	115
66	Pheochromocytoma: an update on genetics and management. <i>Endocrine-Related Cancer</i> , 2007, 14, 935-956.	1.6	114
67	Components of the Metabolic Syndrome and Risk for First-Ever Acute Ischemic Nonembolic Stroke in Elderly Subjects. <i>Stroke</i> , 2005, 36, 1372-1376.	1.0	112
68	European Panel On Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. <i>Current Vascular Pharmacology</i> , 2011, 9, 531-532.	0.8	110
69	Cilostazol for intermittent claudication. <i>The Cochrane Library</i> , 2014, , CD003748.	1.5	107
70	Diagnostic Value of Postprandial Triglyceride Testing in Healthy Subjects: A Meta-Analysis. <i>Current Vascular Pharmacology</i> , 2011, 9, 271-280.	0.8	105
71	The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. <i>Lipids</i> , 2006, 41, 647-654.	0.7	104
72	The Role of Fibrate Treatment in Dyslipidemia: An Overview. <i>Current Pharmaceutical Design</i> , 2013, 19, 3124-3131.	0.9	104

#	ARTICLE	IF	CITATIONS
73	Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. <i>European Heart Journal</i> , 2019, 40, 2870-2879.	1.0	103
74	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2007, 23, 1169-1176.	0.9	102
75	Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154770.	1.5	101
76	Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?. <i>Current Drug Targets</i> , 2010, 11, 122-135.	1.0	100
77	Marital Status, Cardiovascular Diseases, and Cardiovascular Risk Factors: A Review of the Evidence. <i>Journal of Women's Health</i> , 2017, 26, 624-632.	1.5	99
78	Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 266-270.	1.2	97
79	Contrast-Induced Nephropathy. <i>Angiology</i> , 2015, 66, 508-513.	0.8	96
80	Statins and Renal Function. <i>Angiology</i> , 2002, 53, 493-502.	0.8	95
81	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , 2010, 26, 713-719.	0.9	93
82	Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 53-72.	1.4	92
83	The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2010, 8, 437-449.	0.8	90
84	Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. <i>Pharmacological Research</i> , 2013, 72, 35-44.	3.1	90
85	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	3.1	90
86	Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications. <i>Current Pharmaceutical Design</i> , 2007, 13, 3622-3636.	0.9	87
87	Evaluation of the effect of oxidative stress and vitamin E supplementation on renal function in rats with streptozotocin-induced Type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2009, 23, 130-136.	1.2	87
88	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 21-33.	1.5	87
89	Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?. <i>Current Vascular Pharmacology</i> , 2018, 16, 219-227.	0.8	87
90	The Use of Citrated Whole Blood in Thromboelastography. <i>Anesthesia and Analgesia</i> , 2000, 90, 1086-1088.	1.1	85

#	ARTICLE	IF	CITATIONS
91	The mechanisms of atrial fibrillation in hyperthyroidism. <i>Thyroid Research</i> , 2009, 2, 4.	0.7	85
92	Acute pancreatitis in pregnancy: an overview. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 159, 261-266.	0.5	85
93	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1691-1701.	0.9	84
94	Introducing the "Drucebo"™ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	2.9	84
95	Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. <i>Current Medical Research and Opinion</i> , 2007, 23, 2183-2192.	0.9	82
96	Uric Acid and Diabetes: Is there a Link?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4930-4937.	0.9	82
97	Influence of platelet count and activity on thromboelastography parameters. <i>Platelets</i> , 2003, 14, 219-224.	1.1	81
98	The Effect of Short-Term Treatment with Simvastatin on Renal Function in Patients with Peripheral Arterial Disease. <i>Angiology</i> , 2004, 55, 53-62.	0.8	81
99	Statins: An essential component in the management of carotid artery disease. <i>Journal of Vascular Surgery</i> , 2007, 46, 373-386.e9.	0.6	79
100	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. <i>Atherosclerosis</i> , 2008, 200, 1-12.	0.4	79
101	Takotsubo cardiomyopathy " The current state of knowledge. <i>International Journal of Cardiology</i> , 2010, 142, 120-125.	0.8	78
102	Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. <i>Current Medical Research and Opinion</i> , 2011, 27, 1191-1210.	0.9	78
103	Dietary inflammatory index and cardiometabolic risk in US adults. <i>Atherosclerosis</i> , 2018, 276, 23-27.	0.4	78
104	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. <i>Current Medical Research and Opinion</i> , 2013, 29, 1263-1274.	0.9	77
105	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 74-82.	2.3	75
106	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). <i>Clinical Nutrition</i> , 2021, 40, 255-276.	2.3	75
107	The Role of Serotonin (5-Hydroxytryptamine 1A and 1B ) Receptors in Prostate Cancer Cell Proliferation. <i>Journal of Urology</i> , 2006, 176, 1648-1653.	0.2	74
108	Metabolic syndrome and renal disease. <i>International Journal of Cardiology</i> , 2013, 164, 141-150.	0.8	74



#	ARTICLE	IF	CITATIONS
109	Apolipoprotein E Knockout Models. <i>Current Pharmaceutical Design</i> , 2008, 14, 338-351.	0.9	73
110	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011, 5, 796-805.	0.4	72
111	A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. <i>Fertility and Sterility</i> , 2002, 77, 945-951.	0.5	71
112	Effect of nonesterified fatty acids on the stability of prostacyclin activity. <i>Metabolism: Clinical and Experimental</i> , 1983, 32, 717-721.	1.5	70
113	The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. <i>Platelets</i> , 2004, 15, 117-125.	1.1	70
114	Epicardial fat and vascular risk. <i>Current Opinion in Cardiology</i> , 2013, 28, 458-463.	0.8	70
115	Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. <i>Archives of Medical Science</i> , 2020, 16, 485-489.	0.4	70
116	Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2004, 20, 627-637.	0.9	69
117	Dyslipidemia as a Risk Factor for Ischemic Stroke. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 1291-1297.	1.0	69
118	The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. <i>BJU International</i> , 2006, 97, 634-639.	1.3	68
119	Angiotensin II reactivation and aldosterone escape phenomena in reninâ€“angiotensinâ€“aldosterone system blockade: is oral renin inhibition the solution?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 529-535.	0.9	68
120	Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients. <i>American Journal of Cardiology</i> , 2008, 101, 483-485.	0.7	68
121	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , 2009, 8, 163-184.	0.9	68
122	Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. <i>BMC Medicine</i> , 2016, 14, 4.	2.3	68
123	Statins and renal function in patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2003, 19, 615-617.	0.9	67
124	The effects of antiepileptic drugs on vascular risk factors: A narrative review. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2014, 23, 677-684.	0.9	67
125	Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Angiology</i> , 2016, 67, 749-755.	0.8	67
126	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. <i>Metabolism: Clinical and Experimental</i> , 2019, 101, 154001.	1.5	67



#	ARTICLE	IF	CITATIONS
127	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1065-1074.	1.5	66
128	A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?. <i>International Journal of Cardiology</i> , 2013, 168, 5437-5447.	0.8	66
129	Hyperuricaemia. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 397-402.	0.6	66
130	Visfatin/PBEF and Atherosclerosis-Related Diseases. <i>Current Vascular Pharmacology</i> , 2010, 8, 12-28.	0.8	65
131	Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Drugs</i> , 2018, 78, 453-462.	4.9	64
132	Adrenergic modulation of vascular prostacyclin (PGI <sub>2</sub> ) secretion. <i>European Journal of Pharmacology</i> , 1985, 114, 33-40.	1.7	63
133	Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATORvastatin and ROSuvastatin (the ATOROS study). <i>Current Medical Research and Opinion</i> , 2006, 22, 1123-1131.	0.9	63
134	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 717-725.	1.0	63
135	Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. <i>Annals of Medicine</i> , 2018, 50, 1-6.	1.5	63
136	Fenofibrate: Metabolic and Pleiotropic Effects. <i>Current Vascular Pharmacology</i> , 2005, 3, 87-98.	0.8	61
137	Does Diabetes Mellitus Play a Role in Restenosis and Patency Rates Following Lower Extremity Peripheral Arterial Revascularization? A Critical Overview. <i>Annals of Vascular Surgery</i> , 2008, 22, 481-491.	0.4	61
138	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	3.1	61
139	Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 27-33.	1.0	60
140	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2016, 103, 236-252.	3.1	60
141	Lipid-lowering activity of artichoke extracts: A systematic review and meta-analysis. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 2549-2556.	5.4	60
142	Definition of Best Medical Treatment in Asymptomatic and Symptomatic Carotid Artery Stenosis. <i>Angiology</i> , 2016, 67, 411-419.	0.8	59
143	The link between insulin resistance parameters and serum uric acid is mediated by adiposity. <i>Atherosclerosis</i> , 2018, 270, 180-186.	0.4	59
144	The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. <i>European Journal of Pharmacology</i> , 2001, 425, 57-64.	1.7	58

#	ARTICLE	IF	CITATIONS
145	The role of fibrinogen and fibrinolysis in peripheral arterial disease. <i>Thrombosis Research</i> , 2008, 122, 1-12.	0.8	58
146	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. <i>Current Medical Research and Opinion</i> , 2000, 16, 139-146.	0.9	57
147	Value of Thromboelastography in the Assessment of Platelet Function. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 137-142.	0.7	56
148	Obesity and Arterial Compliance Alterations. <i>Current Vascular Pharmacology</i> , 2010, 8, 155-168.	0.8	56
149	Statin + fibrate combination therapy. <i>International Journal of Cardiology</i> , 1999, 69, 237-244.	0.8	55
150	Dyslipidaemia of Obesity, Metabolic Syndrome and Type 2 Diabetes Mellitus: the Case for Residual Risk Reduction After Statin Treatment. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 24-34.	0.6	55
151	The meaning of hypokalemia in heart failure. <i>International Journal of Cardiology</i> , 2012, 158, 12-17.	0.8	55
152	Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2016, 6, 19188.	1.6	55
153	Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. <i>Current Medical Research and Opinion</i> , 2006, 22, 511-528.	0.9	54
154	Optical Techniques in the Assessment of Peripheral Arterial Disease. <i>Current Vascular Pharmacology</i> , 2007, 5, 53-59.	0.8	54
155	Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?. <i>Current Vascular Pharmacology</i> , 2011, 9, 698-705.	0.8	53
156	Thromboxane A2 analogue (U-46619) stimulates vascular PGI2 synthesis. <i>European Journal of Pharmacology</i> , 1985, 107, 259-262.	1.7	52
157	Smoking Diminishes the Beneficial Effect of Statins: Observations from the Landmark Trials. <i>Angiology</i> , 2001, 52, 575-587.	0.8	52
158	Coagulation, Platelets, and Acute Pancreatitis. <i>Pancreas</i> , 2007, 34, 15-20.	0.5	52
159	Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. <i>BJU International</i> , 2008, 101, 106-112.	1.3	52
160	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009, 24, 351-357.	0.8	52
161	PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3869-3877.	0.9	52
162	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. <i>Clinical Nutrition</i> , 2020, 39, 3677-3686.	2.3	52

#	ARTICLE	IF	CITATIONS
163	An update on biomarkers of heart failure in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 1681-1689.	0.3	51
164	Time for new indications for statins?. <i>Medical Science Monitor</i> , 2009, 15, MS1-5.	0.5	51
165	Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels. <i>Angiology</i> , 2002, 53, 273-277.	0.8	50
166	Both the ADP receptors P2Y 1 and P2Y 12 , play a role in controlling shape change in human platelets. <i>Platelets</i> , 2003, 14, 15-20.	1.1	50
167	Peripheral Arterial Disease: A Missed Opportunity to Administer Statins so as to Reduce Cardiac Morbidity and Mortality. <i>Current Medicinal Chemistry</i> , 2005, 12, 443-452.	1.2	50
168	Lone atrial fibrillation: what do we know?. <i>Heart</i> , 2010, 96, 498-503.	1.2	50
169	Consumption of dairy product and its association with total and cause-specific mortality – A population-based cohort study and meta-analysis. <i>Clinical Nutrition</i> , 2019, 38, 2833-2845.	2.3	50
170	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. <i>Hypertension</i> , 2022, 79, 1319-1326.	1.3	50
171	Statins and Peripheral Arterial Disease: Potential Mechanisms and Clinical Benefits. <i>Annals of Vascular Surgery</i> , 2006, 20, 696-705.	0.4	49
172	Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. <i>BJU International</i> , 2008, 102, 108-112.	1.3	49
173	Postoperative Atrial Fibrillation - What Do We Really Know?. <i>Current Vascular Pharmacology</i> , 2010, 8, 553-572.	0.8	49
174	Liver Enzymes: Potential Cardiovascular Risk Markers?. <i>Current Pharmaceutical Design</i> , 2011, 17, 3632-3643.	0.9	49
175	Comparison of the five 2011 guidelines for the treatment of carotid stenosis. <i>Journal of Vascular Surgery</i> , 2012, 55, 1504-1508.	0.6	49
176	Role of Antihypertensive Drugs in Arterial –De-Stiffening–™ and Central Pulsatile Hemodynamics. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 143-156.	1.0	49
177	Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?. <i>Current Vascular Pharmacology</i> , 2016, 14, 432-441.	0.8	49
178	Low serum albumin: A neglected predictor in patients with cardiovascular disease. <i>European Journal of Internal Medicine</i> , 2022, 102, 24-39.	1.0	49
179	Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxigenase activity. <i>FEBS Letters</i> , 1989, 245, 105-109.	1.3	48
180	Cigarette smoking and erectile dysfunction. <i>Perspectives in Public Health</i> , 1998, 118, 151-155.	0.5	48

#	ARTICLE	IF	CITATIONS
181	Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: Where we are now?. <i>Platelets</i> , 2006, 17, 1-6.	1.1	48
182	Internal Carotid Artery Occlusion: Association With Atherosclerotic Disease in Other Arterial Beds and Vascular Risk Factors. <i>Angiology</i> , 2007, 58, 329-335.	0.8	48
183	Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 120-134.	1.0	48
184	Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2021, 27, 1941-1951.	0.9	48
185	Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview. <i>Current Vascular Pharmacology</i> , 2014, 12, 627-641.	0.8	48
186	Apolipoprotein E Polymorphism and Atherosclerosis. <i>Angiology</i> , 2003, 54, 59-71.	0.8	47
187	Mechanisms to explain the poor results of carotid artery stenting (CAS) in symptomatic patients to date and options to improve CAS outcomes. <i>Journal of Vascular Surgery</i> , 2010, 52, 1367-1375.	0.6	47
188	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , 2011, 27, 1659-1668.	0.9	47
189	Near-Infrared Spectroscopy Assessment Following Exercise Training in Patients With Intermittent Claudication and in Untrained Healthy Participants. <i>Vascular and Endovascular Surgery</i> , 2012, 46, 315-324.	0.3	47
190	Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 13.	1.2	47
191	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014, 29, 389-395.	0.8	47
192	Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. <i>Atherosclerosis</i> , 2015, 242, 87-96.	0.4	47
193	Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. <i>International Journal of Cardiology</i> , 2002, 84, 53-57.	0.8	46
194	Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures. <i>Current Drug Targets</i> , 2007, 8, 942-951.	1.0	46
195	Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. <i>BJU International</i> , 2008, 101, 352-359.	1.3	46
196	Vascular risk factors in South Asians. <i>International Journal of Cardiology</i> , 2008, 128, 5-16.	0.8	46
197	Association Between Ankle - Brachial Index and Risk Factor Profile in Patients Newly Diagnosed With Intermittent Claudication. <i>Circulation Journal</i> , 2008, 72, 441-448.	0.7	46
198	HSP 70 and atherosclerosis - protector or activator?. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 307-317.	1.5	46

#	ARTICLE	IF	CITATIONS
199	Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 401-420.	1.5	46
200	IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary heart disease risk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , 2011, 6, 984-992.	0.4	46
201	Definition of Postprandial Lipaemia. <i>Current Vascular Pharmacology</i> , 2011, 9, 292-301.	0.8	46
202	Why Calls for More Routine Carotid Stenting Are Currently Inappropriate. <i>Stroke</i> , 2013, 44, 1186-1190.	1.0	46
203	Editorial: Ageing, Longevity, Exceptional Longevity and Related Genetic and Non Genetics Markers: Panel Statement. <i>Current Vascular Pharmacology</i> , 2014, 12, 659-661.	0.8	46
204	Renal Function Impairment in Peripheral Arterial Disease: An Important Parameter that Should not Be Neglected. <i>Annals of Vascular Surgery</i> , 2009, 23, 690-699.	0.4	45
205	Abdominal aortic aneurysms and diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1330-1336.	1.2	45
206	Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 419-431.	1.3	45
207	Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2006, 4, 175-183.	0.8	44
208	The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation–still underestimated opponent. <i>Europace</i> , 2008, 10, 1266-1270.	0.7	44
209	Statin discontinuation: an underestimated risk?. <i>Current Medical Research and Opinion</i> , 2008, 24, 3059-3062.	0.9	44
210	Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT): A Prospective-Randomized Study in Middle Aged Men and Women. <i>Current Vascular Pharmacology</i> , 2011, 9, 647-657.	0.8	44
211	Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus. <i>Current Pharmaceutical Design</i> , 2019, 25, 2051-2059.	0.9	44
212	Ankle-Brachial Index: A Marker of Both Peripheral Arterial Disease and Systemic Atherosclerosis As Well As a Predictor of Vascular Events. <i>Angiology</i> , 2010, 61, 521-523.	0.8	43
213	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1449-1461.	0.9	43
214	Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 369-380.	0.9	43
215	Homocysteine and diabetes: Role in macrovascular and microvascular complications. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107834.	1.2	43
216	Beyond LDL-C – The Importance of Raising HDL-C. <i>Current Medical Research and Opinion</i> , 2002, 18, 36-44.	0.9	42

#	ARTICLE	IF	CITATIONS
217	Oral and ocular/orbital manifestations of temporal arteritis: a disease with deceptive clinical symptoms and devastating consequences. <i>Clinical Rheumatology</i> , 2007, 26, 1044-1048.	1.0	42
218	C-reactive protein (CRP): more than just an innocent bystander?. <i>Current Medical Research and Opinion</i> , 2008, 24, 75-78.	0.9	42
219	Welcome to CMRO's 40th Anniversary Issue. <i>Current Medical Research and Opinion</i> , 2012, 28, 1-1.	0.9	42
220	Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans. <i>Lipids in Health and Disease</i> , 2017, 16, 192.	1.2	42
221	Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. <i>Molecular Metabolism</i> , 2021, 50, 101049.	3.0	42
222	Carotid Bifurcation Geometry and Atherosclerosis. <i>Angiology</i> , 2017, 68, 757-764.	0.8	41
223	Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3858-3868.	0.9	41
224	Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies. <i>Current Pharmaceutical Design</i> , 2014, 20, 4944-4952.	0.9	41
225	The effect of nitric oxide and peroxynitrite on rabbit cavernosal smooth muscle relaxation. <i>World Journal of Urology</i> , 2001, 19, 220-224.	1.2	40
226	Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey. <i>Angiology</i> , 2005, 56, 279-287.	0.8	40
227	Definitions of Metabolic Syndrome: Where are We Now?. <i>Current Vascular Pharmacology</i> , 2006, 4, 185-197.	0.8	40
228	The Role of Thiols in Liver Ischemia-Reperfusion Injury. <i>Current Pharmaceutical Design</i> , 2006, 12, 2891-2901.	0.9	40
229	Role and significance of statins in the treatment of hypertensive patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 1995-2005.	0.9	40
230	Nutrition During Pregnancy and the Effect of Carbohydrates on the Offspring's Metabolic Profile: In Search of the "Perfect Maternal Diet". <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 103-109.	0.6	40
231	Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver. <i>Clinical Biochemistry</i> , 2011, 44, 1457-1463.	0.8	40
232	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , 2013, 3, 418-426.	0.4	40
233	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	0.6	40
234	Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 92-100.	1.5	40

#	ARTICLE	IF	CITATIONS
235	Ezetimibe Therapy for Dyslipidemia: An Update. <i>Current Pharmaceutical Design</i> , 2013, 19, 3107-3114.	0.9	40
236	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1143-1160.	1.5	39
237	Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?. <i>Annals of Medicine</i> , 2011, 43, 167-171.	1.5	39
238	Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. <i>Nutrition Reviews</i> , 2017, 75, 361-373.	2.6	39
239	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). <i>Progress in Cardiovascular Diseases</i> , 2021, 67, 40-52.	1.6	39
240	Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management. <i>Current Pharmaceutical Design</i> , 2017, 23, 1522-1532.	0.9	39
241	Hemostatic Factors and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2014, 11, 880-905.	0.8	39
242	The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002, 18, 215-219.	0.9	38
243	Nephroprotective and clinical potential of statins in dialyzed patients. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 541-550.	1.5	38
244	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 667-674.	1.0	38
245	Mean platelet volume and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2019, 34, 390-398.	0.8	38
246	The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 3665-3674.	0.9	38
247	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	0.8	38
248	Ethanol Ingestion Inhibits Human Whole Blood Platelet Impedance Aggregation. <i>American Journal of Clinical Pathology</i> , 1987, 88, 342-345.	0.4	37
249	A review of the lipid-related effects of fluvastatin. <i>Current Medical Research and Opinion</i> , 2005, 21, 231-243.	0.9	37
250	The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 642-652.	1.0	37
251	Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. <i>Lipids in Health and Disease</i> , 2009, 8, 24.	1.2	37
252	The effects of statins on blood pressure in normotensive or hypertensive subjects – A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013, 168, 2816-2824.	0.8	37



#	ARTICLE	IF	CITATIONS
253	The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 427-435.	1.9	37
254	Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. <i>Medical Science Monitor</i> , 2009, 15, 203-208.	0.5	37
255	Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term. <i>Circulation Research</i> , 2022, 130, 1276-1285.	2.0	37
256	Vitamin D and Metabolic Syndrome: Is There a Link?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3417-3434.	0.9	36
257	Dapagliflozin: more than just another oral glucose-lowering agent?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1581-1589.	1.9	36
258	Left atrial size in hypertension and stroke. <i>Journal of Hypertension</i> , 2011, 29, 1988-1993.	0.3	36
259	Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2013, 29, 435-451.	0.9	36
260	ETC-1002: A future option for lipid disorders?. <i>Atherosclerosis</i> , 2014, 237, 705-710.	0.4	36
261	Statin Intolerance. <i>Cardiology Clinics</i> , 2018, 36, 225-231.	0.9	36
262	Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Drugs</i> , 2018, 78, 99-109.	4.9	36
263	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018, 50, 565-575.	1.5	36
264	Atherogenesis in Renal Patients: A Model of Vascular Disease?. <i>Current Vascular Pharmacology</i> , 2008, 6, 93-107.	0.8	36
265	The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. <i>Medical Science Monitor</i> , 2009, 15, MS12-23.	0.5	36
266	Effect of Ciprofibrate on Lipoproteins, Fibrinogen, Renal Function, and Hepatic Enzymes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 219-226.	1.0	35
267	The Effect of Apolipoprotein E Polymorphism on the Response to Lipid-Lowering Treatment With Atorvastatin or Fenofibrate. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 211-221.	1.0	35
268	Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. <i>Lipids</i> , 2007, 42, 999-1009.	0.7	35
269	Homocysteine Activates Platelets In Vitro. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 8-18.	0.7	35
270	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 416-421.	0.8	35

#	ARTICLE	IF	CITATIONS
271	The effect of bergamot on dyslipidemia. <i>Phytomedicine</i> , 2016, 23, 1175-1181.	2.3	35
272	Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. <i>Angiology</i> , 2017, 68, 99-108.	0.8	35
273	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1243-1260.	0.9	35
274	The Effects of Lipid-Regulating Therapy on Haemostatic Parameters. <i>Current Pharmaceutical Design</i> , 2003, 9, 2425-2443.	0.9	35
275	Effect of Rosuvastatin on Non-alcoholic Steatohepatitis in Patients with Metabolic Syndrome and Hypercholesterolaemia: A Preliminary Report. <i>Current Vascular Pharmacology</i> , 2014, 12, 505-511.	0.8	35
276	Oxidative Stress As A Common Mediator for Apoptosis Induced-Cardiac Damage in Diabetic Rats. <i>Open Cardiovascular Medicine Journal</i> , 2008, 2, 70-78.	0.6	35
277	The role of polyphenols in cardiovascular disease. <i>Medical Science Monitor</i> , 2010, 16, RA110-9.	0.5	35
278	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1596-1622.	2.9	35
279	Mean platelet volume as an indicator of platelet activation: methodological issues. <i>Platelets</i> , 2003, 14, 335-336.	1.1	34
280	Smooth Muscle and Purinergic Contraction of the Human, Rabbit, Rat, and Mouse Testicular Capsule1. <i>Biology of Reproduction</i> , 2006, 74, 473-480.	1.2	34
281	ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 673-681.	0.8	34
282	Bilirubin Levels and Their Association with Carotid Intima Media Thickness and High-Sensitivity C-reactive Protein in Patients with Psoriasis Vulgaris. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 137-142.	3.3	34
283	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>Cardiovascular Research</i> , 2019, 115, 204-212.	1.8	34
284	Pioglitazone and Cancer: Angel or Demon?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4913-4929.	0.9	34
285	Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. <i>International Urology and Nephrology</i> , 2011, 43, 491-498.	0.6	33
286	Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 521-522.	1.2	33
287	Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells. <i>Anticancer Research</i> , 2004, 24, 2853-9.	0.5	33
288	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , 2004, 66, 1714-1715.	2.6	32

#	ARTICLE	IF	CITATIONS
289	Prospective Assessment of Lower-Extremity Peripheral Arterial Disease in Diabetic Patients Using a Novel Automated Optical Device. <i>Angiology</i> , 2007, 58, 579-585.	0.8	32
290	Metformin and cancer: licence to heal?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 913-917.	1.9	32
291	Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 647-655.	0.9	32
292	Triglycerides. <i>Current Opinion in Cardiology</i> , 2012, 27, 398-404.	0.8	32
293	Pleiotropic Effects of Nicotinic Acid: Beyond High Density Lipoprotein Cholesterol Elevation. <i>Current Vascular Pharmacology</i> , 2011, 9, 385-400.	0.8	32
294	Effect of milrinone on human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study. <i>Thrombosis Research</i> , 1993, 71, 227-236.	0.8	31
295	Metabolic syndrome and gender differences in postprandial lipaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 661-664.	3.1	31
296	Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation. <i>Current Drug Targets</i> , 2006, 7, 761-771.	1.0	31
297	Combined Treatment With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: A Review of the Current Evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 1-15.	1.0	31
298	The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure. <i>Current Vascular Pharmacology</i> , 2006, 4, 89-93.	0.8	31
299	Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 851-866.	1.5	31
300	Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years. <i>Current Vascular Pharmacology</i> , 2011, 9, 62-86.	0.8	31
301	What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1835-1844.	0.9	31
302	An evaluation of RVX-208 for the treatment of atherosclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1389-1398.	1.9	31
303	Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 188.	1.2	31
304	Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. <i>Journal of the American College of Nutrition</i> , 2019, 38, 552-563.	1.1	31
305	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. <i>Archives of Medical Science</i> , 2019, 15, 1357-1364.	0.4	31
306	Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179.	2.1	31

#	ARTICLE	IF	CITATIONS
307	The Effect of Statins on Postprandial Lipemia. <i>Current Drug Targets</i> , 2007, 8, 551-560.	1.0	30
308	Thromboangiitis Obliterans (Buerger's Disease): Searching for a Therapeutic Strategy. <i>Angiology</i> , 2007, 58, 75-84.	0.8	30
309	In-hospital mortality for pulmonary embolism: relationship with chronic kidney disease and end-stage renal disease. The hospital admission and discharge database of the Emilia Romagna region of Italy. <i>Internal and Emergency Medicine</i> , 2013, 8, 735-740.	1.0	30
310	Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. <i>International Journal of Cardiology</i> , 2019, 276, 242-247.	0.8	30
311	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. <i>Platelets</i> , 2005, 16, 65-71.	1.1	29
312	Involvement of ERK1/2 Kinase in Insulin-and Thrombin-Stimulated Vascular Smooth Muscle Cell Proliferation. <i>Angiology</i> , 2010, 61, 357-364.	0.8	29
313	Regulation of inducible nitric oxide synthase activity/expression in rat hearts from ghrelin-treated rats. <i>Journal of Physiology and Biochemistry</i> , 2011, 67, 195-204.	1.3	29
314	Subclinical hypothyroidism and vascular risk: An update. <i>Hormones</i> , 2013, 12, 495-506.	0.9	29
315	The Epsilon 2 and 4 Alleles of Apolipoprotein E and Ischemic Vascular Events in the Greek Population – Implications for the Interpretation of Similar Studies. <i>Angiology</i> , 2003, 54, 51-58.	0.8	28
316	Primary and Secondary Hypertriglyceridaemia. <i>Current Drug Targets</i> , 2009, 10, 336-343.	1.0	28
317	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2605-2611.	0.9	28
318	Peroxisome Proliferator-Activated Receptors and Atherosclerosis. <i>Angiology</i> , 2011, 62, 523-534.	0.8	28
319	Optimal statin type and dosage for vascular patients. <i>Journal of Vascular Surgery</i> , 2011, 53, 837-844.	0.6	28
320	The Relation Between No-Reflow Phenomenon and Complete Blood Count Parameters. <i>Angiology</i> , 2017, 68, 381-388.	0.8	28
321	Abnormal Peri-Organ or Intra-Organ Fat Deposition and Vascular Risk. <i>Angiology</i> , 2018, 69, 841-842.	0.8	28
322	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	0.8	28
323	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus – a special reference to statins. <i>Journal of Diabetes and Its Complications</i> , 2001, 15, 211-226.	1.2	27
324	The Effect of a Loading Dose (300 mg) of Clopidogrel on Platelet Function in Patients with Peripheral Arterial Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 115-120.	0.7	27

#	ARTICLE	IF	CITATIONS
325	Identifying and Attaining LDL-C Goals: Mission Accomplished? Next Target: New Therapeutic Options to Raise HDL-C Levels. <i>Current Drug Targets</i> , 2007, 8, 483-488.	1.0	27
326	Are Statins an Option in the Management of Abdominal Aortic Aneurysms?. <i>Vascular and Endovascular Surgery</i> , 2008, 42, 128-134.	0.3	27
327	Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies. <i>Current Drug Targets</i> , 2009, 10, 320-327.	1.0	27
328	Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2010, 8, 820-830.	0.8	27
329	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , 2010, 25, 394-398.	0.8	27
330	Association of Reduced Zinc Status With Angiographically Severe Coronary Atherosclerosis: A Pilot Study. <i>Angiology</i> , 2010, 61, 449-455.	0.8	27
331	Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis. <i>Atherosclerosis</i> , 2011, 214, 11-19.	0.4	27
332	Statins and new-onset diabetes mellitusâ€”a matter for debate. <i>Nature Reviews Endocrinology</i> , 2012, 8, 133-134.	4.3	27
333	Long-Term Impact of Multifactorial Treatment on New-Onset Diabetes and Related Cardiovascular Events in Metabolic Syndrome. <i>Angiology</i> , 2012, 63, 358-366.	0.8	27
334	Metformin and heart failure: never say never again. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1-8.	0.9	27
335	Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update. <i>Current Vascular Pharmacology</i> , 2013, 11, 112-120.	0.8	27
336	New statin guidelines and promising novel therapeutics. <i>Nature Reviews Cardiology</i> , 2014, 11, 72-74.	6.1	27
337	Statin loading in cardiovascular surgery. <i>Current Opinion in Cardiology</i> , 2018, 33, 436-443.	0.8	27
338	Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies. <i>Atherosclerosis</i> , 2020, 296, 49-58.	0.4	27
339	Alcohol and the Cardiovascular System: A Double-Edged Sword. <i>Current Pharmaceutical Design</i> , 2014, 20, 6276-6288.	0.9	27
340	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease PatientsÂ§. <i>Open Cardiovascular Medicine Journal</i> , 2007, 1, 8-14.	0.6	27
341	Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance. <i>World Journal of Urology</i> , 1999, 17, 290-295.	1.2	26
342	Endothelin-1 and Human Platelets. <i>Current Vascular Pharmacology</i> , 2005, 3, 393-399.	0.8	26

#	ARTICLE	IF	CITATIONS
343	Alcohol Use, Vascular Disease, and Lipid-Lowering Drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 1-7.	1.3	26
344	Anti-Inflammatory Effects of Fibrates: An Overview. <i>Current Medicinal Chemistry</i> , 2009, 16, 676-684.	1.2	26
345	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , 2010, 32, 326-331.	0.6	26
346	Dyslipidaemia in type 2 diabetes mellitus. <i>Current Opinion in Cardiology</i> , 2017, 32, 422-429.	0.8	26
347	Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease. <i>Lipids in Health and Disease</i> , 2017, 16, 254.	1.2	26
348	Vitamin D status and circulating biomarkers of endothelial dysfunction and inflammation in non-diabetic obese individuals: a pilot study. <i>Archives of Medical Science</i> , 2017, 1, 53-60.	0.4	26
349	Improvement of endothelial function by pitavastatin: a meta-analysis. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 279-286.	0.9	26
350	Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates. <i>Current Medical Research and Opinion</i> , 2000, 16, 21-32.	0.9	26
351	The Treatment of Hypertension in Patients with Erectile Dysfunction. <i>Current Medical Research and Opinion</i> , 2000, 16, s31-s36.	0.9	25
352	The Choice of Antihypertensive Drugs in Patients with Erectile Dysfunction. <i>Current Medical Research and Opinion</i> , 2002, 18, 103-107.	0.9	25
353	The role of serotonin in tumour growth (Review). <i>Oncology Reports</i> , 2005, 14, 1593.	1.2	25
354	Analysis of antihypertensive effects of statins. <i>Current Hypertension Reports</i> , 2007, 9, 175-183.	1.5	25
355	Editorial: [Pleiotropic Effects of Statins: Implications for a Wide Range of Diseases]. <i>Current Vascular Pharmacology</i> , 2008, 6, 237-239.	0.8	25
356	The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up. <i>Lipids in Health and Disease</i> , 2013, 12, 47.	1.2	25
357	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. <i>Current Medical Research and Opinion</i> , 2015, 31, 221-228.	0.9	25
358	New-Onset Diabetes and Statins: Throw the Bath Water Out, But, Please, Keep the Baby!. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 471-475.	1.5	25
359	Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. <i>Scientific Reports</i> , 2016, 6, 30060.	1.6	25
360	Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey. <i>European Heart Journal</i> , 2018, 39, 3635-3640.	1.0	25

#	ARTICLE	IF	CITATIONS
361	Muscarinic stimulation of prostacyclin synthesis by the rat penis. <i>European Journal of Pharmacology</i> , 1986, 123, 67-71.	1.7	24
362	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 191-205.	1.5	24
363	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , 2008, 15, 693-700.	1.6	24
364	Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension. <i>Clinical and Experimental Hypertension</i> , 2009, 31, 20-30.	0.5	24
365	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. <i>Journal of Hypertension</i> , 2011, 29, 2493-2494.	0.3	24
366	Editorial [Hot Topic: New Developments in the Prevention and Treatment of Vascular Disease - 2 Executive (Guest Editors: Manfredi Rizzo and Dimitri P. Mikhailidis)]. <i>Current Pharmaceutical Design</i> , 2011, 17, 3608-3610.	0.9	24
367	Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?. <i>Current Pharmaceutical Design</i> , 2011, 17, 3644-3655.	0.9	24
368	Short-term statin therapy for prevention of contrast-induced AKI. <i>Nature Reviews Nephrology</i> , 2014, 10, 8-9.	4.1	24
369	Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes. <i>Nephron</i> , 2015, 131, 34-42.	0.9	24
370	Contrast-Induced Acute Kidney Injury in Patients Undergoing Carotid Artery Stenting: An Underestimated Issue. <i>Angiology</i> , 2017, 68, 752-756.	0.8	24
371	Homocysteine and Non-Cardiac Vascular Disease. <i>Current Pharmaceutical Design</i> , 2017, 23, 3224-3232.	0.9	24
372	Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. <i>Atherosclerosis</i> , 2019, 284, 44-49.	0.4	24
373	Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved?. <i>Anticancer Research</i> , 2005, 25, 4281-6.	0.5	24
374	Efficacy of remote ischaemic preconditioning for spinal cord protection against ischaemic injury: association with heat shock protein expression. <i>Folia Neuropathologica</i> , 2008, 46, 204-12.	0.5	24
375	Naftidrofuryl inhibits the release of 5-hydroxytryptamine and platelet-derived growth factor from human platelets. <i>Clinica Chimica Acta</i> , 1994, 230, 157-167.	0.5	23
376	Drug Treatment of Combined Hyperlipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 327-336.	1.0	23
377	Effect of Atorvastatin on Serum Creatinine Levels. <i>Current Medical Research and Opinion</i> , 2001, 17, 230-231.	0.9	23
378	Association of Apolipoprotein E Genotype with Early Onset of Coronary Heart Disease in Greek Men. <i>Angiology</i> , 2005, 56, 663-670.	0.8	23



#	ARTICLE	IF	CITATIONS
379	The involvement of professional medical writers in medical publications. <i>Current Medical Research and Opinion</i> , 2005, 21, 307-309.	0.9	23
380	Atherosclerotic Renal Artery Stenosis: Association with Emerging Vascular Risk Factors. <i>Nephron Clinical Practice</i> , 2008, 108, c56-c66.	2.3	23
381	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010, 25, 406-410.	0.8	23
382	Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: â€ˆA new kid on the blockâ€™?. <i>Annals of Medicine</i> , 2011, 43, 249-258.	1.5	23
383	Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?). <i>Current Vascular Pharmacology</i> , 2012, 10, 374-377.	0.8	23
384	Are statins â€ˆIDEALâ€™ for non-alcoholic fatty liver disease?. <i>Current Medical Research and Opinion</i> , 2014, 30, 229-231.	0.9	23
385	Ear lobe crease: a marker of coronary artery disease?. <i>Archives of Medical Science</i> , 2015, 6, 1145-1155.	0.4	23
386	Lung and kidney: a dangerous liaison? A population-based cohort study in COPD patients in Italy. <i>International Journal of COPD</i> , 2017, Volume 12, 443-450.	0.9	23
387	Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 565-569.	1.2	23
388	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2019, 17, 538-540.	0.8	23
389	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. <i>Endocrine</i> , 2020, 69, 249-261.	1.1	23
390	Lipids, Statins and Heart Failure: An Update. <i>Current Pharmaceutical Design</i> , 2016, 22, 4796-4806.	0.9	23
391	Cholesteryl Ester Transfer Protein Gene Polymorphisms and Longevity Syndrome. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 14-19.	0.6	23
392	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1593-1599.	0.9	22
393	Diabetes and Antioxidants: Myth or Reality?. <i>Current Vascular Pharmacology</i> , 2010, 8, 661-672.	0.8	22
394	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 723-730.	0.9	22
395	Cardiac Adaptive Responses After Hypoxia in an Experimental Model. <i>Angiology</i> , 2010, 61, 145-156.	0.8	22
396	Contrast-Induced Nephropathy and the Vascular Patient. <i>Angiology</i> , 2010, 61, 721-723.	0.8	22

#	ARTICLE	IF	CITATIONS
397	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , 2010, 26, 839-842.	0.9	22
398	Could carbon monoxide and bilirubin be friends as well as foes of the body?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 1-5.	0.6	22
399	Lipid Lowering Drugs and Gallstones: A Therapeutic Option?. <i>Current Pharmaceutical Design</i> , 2011, 17, 3622-3631.	0.9	22
400	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 392-397.	0.8	22
401	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457.	0.8	22
402	Effects of oral hypoglycemic agents on platelet function. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 846-851.	1.2	22
403	Assessment of postprandial triglycerides in clinical practice: Validation in a general population and coronary heart disease patients. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1163-1171.	0.6	22
404	Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. <i>Current Vascular Pharmacology</i> , 2022, 20, 96-110.	0.8	22
405	A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. <i>Current Pharmaceutical Design</i> , 2013, 19, 4953-4963.	0.9	22
406	Apolipoprotein J and leptin levels in patients with coronary heart disease. <i>In Vivo</i> , 2008, 22, 537-42.	0.6	22
407	Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?. <i>Medical Science Monitor</i> , 2009, 15, MS24-30.	0.5	22
408	Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in) Tj ETQq0 0 0 rgBT /Overlock 10 T 2008, 24, 2467-2476.	0.9	21
409	The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women. <i>Current Pharmaceutical Design</i> , 2009, 15, 1054-1062.	0.9	21
410	Point of care testing is appropriate for National Health Service health check. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 159-165.	0.8	21
411	Association Between Epicardial Fat Thickness and Weight Homeostasis Hormones in Patients With Noncachectic Heart Failure. <i>Angiology</i> , 2013, 64, 173-180.	0.8	21
412	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. <i>Archives of Medical Science</i> , 2013, 5, 788-795.	0.4	21
413	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	3.1	21
414	Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2007-2017.	0.9	21

#	ARTICLE	IF	CITATIONS
415	The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future. <i>Angiology</i> , 2020, 71, 10-16.	0.8	21
416	Adverse Impact of <i>Desulfovibrio</i> spp. and Beneficial Role of <i>Anaerostipes</i> spp. on Renal Function: Insights from a Mendelian Randomization Analysis. <i>Nutrients</i> , 2020, 12, 2216.	1.7	21
417	Management of Patients with Asymptomatic Carotid Stenosis May Need to Be Individualized: A Multidisciplinary Call for Action. <i>Journal of Stroke</i> , 2021, 23, 202-212.	1.4	21
418	Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications. <i>Current Medicinal Chemistry</i> , 2020, 27, 1021-1040.	1.2	21
419	Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2014, 20, 6299-6305.	0.9	21
420	Upregulation of Endothelin A Receptor Sites in the Rabbit Diabetic Kidney: Potential Relevance to the Early Pathogenesis of Diabetic Nephropathy. <i>Nephron</i> , 1999, 83, 261-267.	0.9	20
421	Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2459-2463.	0.9	20
422	Metallothionein expression in the high-risk carotid atherosclerotic plaque. <i>Current Medical Research and Opinion</i> , 2007, 23, 659-670.	0.9	20
423	Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. <i>International Urology and Nephrology</i> , 2010, 42, 999-1006.	0.6	20
424	Hypertension and kidney disease. <i>Journal of Hypertension</i> , 2012, 30, 457-462.	0.3	20
425	Cardiovascular Risk Assessment in Diabetes Mellitus. <i>Angiology</i> , 2013, 64, 336-342.	0.8	20
426	Pro-sarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 331-353.	4.0	20
427	Cilostazol for intermittent claudication. <i>The Cochrane Library</i> , 2021, 2021, CD003748.	1.5	20
428	Psoriasis and Vascular Risk: An Update. <i>Current Pharmaceutical Design</i> , 2014, 20, 6114-6125.	0.9	20
429	Evaluation of Aortic Stiffness (Aortic Pulse-Wave Velocity) Before and After Elective Abdominal Aortic Aneurysm Repair Procedures: A Pilot Study#. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 173-175.	0.6	20
430	The Role of Psychobiological and Neuroendocrine Mechanisms in Appetite Regulation and Obesity. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 147-155.	0.6	20
431	Atrial fibrillation as a nonpsychiatric predictor of delirium after cardiac surgery: a pilot study. <i>Medical Science Monitor</i> , 2008, 14, CR286-291.	0.5	20
432	Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and $^{45}\text{Ca}^{2+}$ uptake by human platelets. <i>European Journal of Pharmacology</i> , 1993, 245, 67-73.	2.7	19

#	ARTICLE	IF	CITATIONS
433	Do Different Vascular Risk Factors Affect All Arteries Equally?. <i>Angiology</i> , 2008, 59, 397-401.	0.8	19
434	Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes. <i>Angiology</i> , 2010, 61, 584-590.	0.8	19
435	Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2011, 17, 3699-3712.	0.9	19
436	Review: Antiplatelet Drugs: What Comes Next?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 9-26.	0.7	19
437	The Rationale for Lowering the Size Threshold in Elective Endovascular Repair of Abdominal Aortic Aneurysm. <i>Journal of Endovascular Therapy</i> , 2011, 18, 308-313.	0.8	19
438	Aging Men and Lipids. <i>American Journal of Men's Health</i> , 2011, 5, 152-165.	0.7	19
439	Optimal contemporary management of symptomatic and asymptomatic carotid artery stenosis. <i>Vascular</i> , 2011, 19, 117-120.	0.4	19
440	All for Statins and Statins for All; An Update. <i>Current Pharmaceutical Design</i> , 2015, 22, 18-27.	0.9	19
441	Endocan and Atherosclerosis. <i>Angiology</i> , 2015, 66, 490-490.	0.8	19
442	A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. <i>Pharmacological Research</i> , 2016, 111, 343-356.	3.1	19
443	Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. <i>Metabolism: Clinical and Experimental</i> , 2017, 74, 43-46.	1.5	19
444	Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor- $\alpha$ concentrations: A systematic review and meta-analysis of controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1458-1464.	1.2	19
445	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 801-809.	0.6	19
446	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 19-26.	1.7	19
447	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	0.8	19
448	Lipoprotein (a) and Cardiovascular Risk: The Show Must go on. <i>Current Medicinal Chemistry</i> , 2017, 24, 989-1006.	1.2	19
449	The Impact of Smoking on Cardiovascular Outcomes and Comorbidities in Statin-treated Patients with Coronary Artery Disease: A Post hoc Analysis of the GREACE Study. <i>Current Vascular Pharmacology</i> , 2013, 11, 779-784.	0.8	19
450	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. <i>Current Vascular Pharmacology</i> , 2019, 17, 515-537.	0.8	19

#	ARTICLE	IF	CITATIONS
451	Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. <i>In Vivo</i> , 2009, 23, 797-812.	0.6	19
452	Altered prostacyclin synthesis by aortae from hepatic portal vein-constricted rats: evidence for effects on protein kinase C and calcium. <i>Journal of Hepatology</i> , 1994, 21, 1017-1022.	1.8	18
453	The Influence of Natural Menopause on Postprandial Lipemia in Heterozygotes for Familial Hypercholesterolemia. <i>Journal of Women's Health</i> , 2004, 13, 1119-1126.	1.5	18
454	Statins and renal function. Is the compound and dose making a difference?. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 963-964.	0.4	18
455	Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and postprandial plasma lipoprotein levels in heterozygotes for familial hypercholesterolemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1190-8.	1.4	18
456	Association between plasma levels and immunolocalization of cytokines in heart valve lesions: a possible target for treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 1209-1215.	1.5	18
457	<i>&lt;i&gt;Cholesterol Crystal Embolization&lt;/i&gt;</i> : A Possible Complication of Peripheral Endovascular Interventions. <i>Journal of Endovascular Therapy</i> , 2008, 15, 614-625.	0.8	18
458	Radial Artery Catheterization for Percutaneous Vascular or Coronary Interventions: An Innocent Procedure?. <i>Angiology</i> , 2010, 61, 5-7.	0.8	18
459	Pulmonary arterial hypertension and statins: an update. <i>Current Opinion in Cardiology</i> , 2011, 26, 322-326.	0.8	18
460	Editorial [Carotid Intima-Media Thickness and Ezetimibe: The End of a Misunderstanding?]. <i>Current Vascular Pharmacology</i> , 2011, 9, 381-384.	0.8	18
461	Statins and dilated cardiomyopathy: do we have enough data?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 315-323.	1.9	18
462	Lipid Lowering Agents and the Endothelium: An Update after 4 Years. <i>Current Vascular Pharmacology</i> , 2012, 10, 33-41.	0.8	18
463	Dronedarone: An overview. <i>Annals of Medicine</i> , 2012, 44, 60-72.	1.5	18
464	Letter to the Editor Obstructive sleep apnoea syndrome and cardiovascular risk. <i>Archives of Medical Science</i> , 2012, 6, 1115-1116.	0.4	18
465	Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 603-610.	1.9	18
466	Mean Platelet Volume and Platelet Distribution Width in Patients With Obstructive Sleep Apnea Syndrome and Concurrent Chronic Obstructive Pulmonary Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1216-1222.	0.7	18
467	Dietary choline is positively related to overall and cause-specific mortality: results from individuals of the National Health and Nutrition Examination Survey and pooling prospective data. <i>British Journal of Nutrition</i> , 2019, 122, 1262-1270.	1.2	18
468	Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2125-2135.	0.9	18

#	ARTICLE	IF	CITATIONS
469	The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. <i>Atherosclerosis Supplements</i> , 2020, 42, e15-e24.	1.2	18
470	The Challenges in Moving from Ageing to Successful Longevity. <i>Current Vascular Pharmacology</i> , 2013, 12, 662-673.	0.8	18
471	Direct measurement of hepatic tissue hypoxia by using a novel tcp O <sub>2</sub> /p CO <sub>2</sub> monitoring system in comparison with near-infrared spectroscopy. <i>Liver International</i> , 2003, 23, 163-170.	1.9	17
472	Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels in Patients with Essential Hypertension. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2005, 11, 139-146.	0.7	17
473	Doxazosin and Serotonin (5-HT) Receptor (1A, 2A, and 4) Antagonists Inhibit 5-HT-Mediated Human Cavensal Contraction. <i>Journal of Andrology</i> , 2006, 27, 679-685.	2.0	17
474	Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 139-147.	0.6	17
475	Should a statin be prescribed to every patient with heart failure?. <i>Heart Failure Reviews</i> , 2008, 13, 211-225.	1.7	17
476	Editorial Are we getting to lipid targets in real life?. <i>Archives of Medical Science</i> , 2010, 5, 639-641.	0.4	17
477	Obstructive Sleep Apnea and Cardiovascular Risk. <i>Angiology</i> , 2012, 63, 569-573.	0.8	17
478	Prevalence of Metabolic Syndrome According to Different Definitions in a Hypertensive Population. <i>Angiology</i> , 2012, 63, 39-47.	0.8	17
479	Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets. <i>Archives of Medical Science</i> , 2012, 4, 598-600.	0.4	17
480	Contrast-induced acute kidney injury in diabetes mellitus: Clinical relevance and predisposing factors. Could statins be of benefit?. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 982-984.	1.2	17
481	Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection?. <i>Angiology</i> , 2019, 70, 581-583.	0.8	17
482	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020, 155, 104719.	3.1	17
483	Can We Decrease Epicardial and Pericardial Fat in Patients With Diabetes?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 107424842110069.	1.0	17
484	Colesevelam: A New and Improved Bile Acid Sequestrant?. <i>Current Pharmaceutical Design</i> , 2013, 19, 3115-3123.	0.9	17
485	Endocrine Hypertension: Diagnosis and Management of a Complex Clinical Entity. <i>Current Vascular Pharmacology</i> , 2010, 8, 646-660.	0.8	17
486	The Impact of Lower Extremity Venous Ulcers due to Chronic Venous Insufficiency on Quality of Life – 2008-11-17 – 2008-11-19 – 2008-11-28 –!. <i>Open Cardiovascular Medicine Journal</i> , 2008, 2, 105-109.	0.6	17

#	ARTICLE	IF	CITATIONS
487	Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. <i>Hellenic Journal of Cardiology</i> , 2005, 46, 380-6.	0.4	17
488	Differential inhibitory potencies of non-steroidal antiinflammatory drugs on smooth muscle prostanoid synthesis. <i>European Journal of Pharmacology</i> , 1990, 182, 83-89.	1.7	16
489	Relaxation of rabbit lower urinary tract smooth muscle by nitric oxide and carbon monoxide: modulation by hydrogen peroxide. <i>European Journal of Pharmacology</i> , 2000, 387, 329-335.	1.7	16
490	Attaining United Kingdom-European Atherosclerosis Society Low-density Lipoprotein Cholesterol Guideline Target Values in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002, 18, 499-502.	0.9	16
491	Association Between Abnormal Uterine Artery Doppler Flow Velocimetry, Risk of Preeclampsia, and Indices of Arterial Structure and Function: A Pilot Study. <i>Angiology</i> , 2008, 59, 493-499.	0.8	16
492	Clinical significance of carotid bruits: an innocent finding or a useful warning sign?. <i>Neurological Research</i> , 2008, 30, 523-530.	0.6	16
493	High Density Lipoprotein Cholesterol and Statin Trials. <i>Current Medicinal Chemistry</i> , 2008, 15, 2265-2270.	1.2	16
494	Should the Size Threshold for Elective Abdominal Aortic Aneurysm Repair be Lowered in the Endovascular Era? Yes. <i>Angiology</i> , 2010, 61, 617-619.	0.8	16
495	Lipid-lowering agents and new onset diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1965-1970.	0.9	16
496	Ezetimibe in diabetes: more than cholesterol lowering?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2517-2520.	0.9	16
497	Effect of Angiotensin II and its Receptor Antagonists on Human Corpus Cavernous Contractility and Oxidative Stress: Modulation of Nitric Oxide Mediated Relaxation. <i>Journal of Urology</i> , 2011, 185, 2414-2420.	0.2	16
498	Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. <i>International Journal of Cardiology</i> , 2018, 272, 316-322.	0.8	16
499	Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 129, 699-704.	0.6	16
500	Endocan: a new marker of endothelial function. <i>Current Opinion in Cardiology</i> , 2021, 36, 462-468.	0.8	16
501	Perivascular Adipose Tissue: Pathophysiological Links With Inflammation, Atherosclerosis, and Thrombosis. <i>Angiology</i> , 2022, 73, 195-196.	0.8	16
502	Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2014, 12, 572-585.	0.8	16
503	Implementation of Guidelines for the Management of Arterial Hypertension. The Impulsion Study. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 26-34.	0.6	16
504	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. <i>PLoS ONE</i> , 2021, 16, e0260313.	1.1	16



#	ARTICLE	IF	CITATIONS
505	Improvement of Ketoacidosis in the Diabetic Rat after the Administration of the Oral Antilipolytic Agent Gr 79236. <i>Clinical Science</i> , 1994, 86, 593-598.	1.8	15
506	Doxazosin modifies serotonin-mediated rabbit urinary bladder contraction. <i>Urological Research</i> , 2000, 28, 116-121.	1.5	15
507	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>Current Medical Research and Opinion</i> , 2004, 20, 1385-1392.	0.9	15
508	Omega-3 fatty acids: How can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , 2008, 10, 510-517.	2.0	15
509	A functional study of purinergic signalling in the normal and pathological rabbit corpus cavernosum. <i>BJU International</i> , 2008, 101, 1043-1047.	1.3	15
510	Vernakalant hydrochloride for the treatment of atrial fibrillation. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1929-1937.	1.9	15
511	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 142-145.	1.2	15
512	Increased risk for cardiovascular disease in patients with obstructive sleep apnoea syndrome&#x2013;chronic obstructive pulmonary disease (overlap syndrome). <i>Clinical Respiratory Journal</i> , 2019, 13, 708-715.	0.6	15
513	Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?. <i>Current Pharmaceutical Design</i> , 2013, 19, 4964-4980.	0.9	15
514	Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. <i>In Vivo</i> , 2007, 21, 685-94.	0.6	15
515	Time-dependent up-regulation of neuronal 5-hydroxytryptamine binding sites in the detrusor of a rabbit model of partial bladder outlet obstruction. <i>World Journal of Urology</i> , 1999, 17, 255-260.	1.2	14
516	Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2004, 10, 9-18.	0.7	14
517	Effect of tibolone on markers of cardiovascular disease risk in postmenopausal women undergoing hemodialysis: a pilot study. <i>Fertility and Sterility</i> , 2004, 81, 1624-1631.	0.5	14
518	The Effect of Cholesterol-Lowering Treatment on Renal Function. <i>American Journal of Kidney Diseases</i> , 2006, 47, 561.	2.1	14
519	Experimental Models of Abdominal Aortic Aneurysms: An Overview. <i>Current Pharmaceutical Design</i> , 2008, 14, 325-337.	0.9	14
520	Cardiovascular Risk Factors and Estimated 10-Year Risk of Fatal Cardiovascular Events Using Various Equations in Greeks With Metabolic Syndrome. <i>Angiology</i> , 2010, 61, 49-57.	0.8	14
521	Emerging options in the treatment of dyslipidemias: a bright future?. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 247-270.	1.0	14
522	Stage of chronic kidney disease and severity of coronary heart disease manifestation. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 457-460.	0.9	14

#	ARTICLE	IF	CITATIONS
523	Should raising high-density lipoprotein cholesterol be a matter of debate?. Journal of Cardiovascular Medicine, 2012, 13, 254-259.	0.6	14
524	Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. Expert Opinion on Pharmacotherapy, 2012, 13, 1985-1988.	0.9	14
525	Uric acid, chronic kidney disease and type 2 diabetes: A cluster of vascular risk factors. Journal of Diabetes and Its Complications, 2014, 28, 122-123.	1.2	14
526	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. Current Medical Research and Opinion, 2016, 32, 1513-1514.	0.9	14
527	Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes and Endocrinology, 2017, 5, 329-330.	5.5	14
528	Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults. British Journal of Nutrition, 2018, 120, 1272-1278.	1.2	14
529	Non-alcoholic fatty liver disease and colorectal cancer: A marker of risk or common causation?. Metabolism: Clinical and Experimental, 2018, 87, A10-A13.	1.5	14
530	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1. Expert Opinion on Drug Safety, 2018, 17, 875-892.	1.0	14
531	Association of Empirical Dietary Atherogenic Indices with All-Cause and Cause-Specific Mortality in a Multi-Ethnic Adult Population of the United States. Nutrients, 2019, 11, 2323.	1.7	14
532	Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: A “non-invasive alternative” to liver biopsy?. Metabolism: Clinical and Experimental, 2019, 101, 154010.	1.5	14
533	Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies. Vascular Disease Prevention, 2004, 1, 243-253.	0.2	14
534	Management of Statin-Intolerant High-Risk Patients. Current Vascular Pharmacology, 2010, 8, 632-637.	0.8	14
535	Ageing Mechanisms and Associated Lipid Changes. Current Vascular Pharmacology, 2013, 12, 682-689.	0.8	14
536	Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106182.	0.7	14
537	A thesis for all seasons. Nature, 1991, 353, 789-790.	13.7	13
538	Endothelin and erectile dysfunction: a target for pharmacological intervention?. Expert Opinion on Investigational Drugs, 1998, 7, 1759-1767.	1.9	13
539	Possible Role of Endothelin-1 in the Rabbit Urinary Bladder Hyperplasia Secondary to Partial Bladder Outlet Obstruction. Scandinavian Journal of Urology and Nephrology, 2000, 34, 15-20.	1.4	13
540	Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, 145-147.	1.0	13

#	ARTICLE	IF	CITATIONS
541	Letter to the Editor. Vascular and Endovascular Surgery, 2007, 41, 87-87.	0.3	13
542	Gene therapy and erectile dysfunction: the current status. Asian Journal of Andrology, 2007, 9, 8-15.	0.8	13
543	Antisense technology for the prevention or the treatment of cardiovascular disease: The next blockbuster?. Expert Opinion on Investigational Drugs, 2008, 17, 969-972.	1.9	13
544	Does Gender Influence the Patency of Infrainguinal Bypass Grafts?. Angiology, 2008, 59, 278-282.	0.8	13
545	The Effect of Tirofiban on Fibrinogen/Agonist-Induced Platelet Shape Change and Aggregation. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 295-302.	0.7	13
546	The GALA Trial: Will It Influence Clinical Practice?. Vascular and Endovascular Surgery, 2009, 43, 429-432.	0.3	13
547	The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis. Current Vascular Pharmacology, 2010, 8, 792-803.	0.8	13
548	Incidence of end-stage renal disease in the elderly: a steadily rising global socioeconomic epidemic. International Urology and Nephrology, 2010, 42, 523-525.	0.6	13
549	Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Current Medical Research and Opinion, 2011, 27, 693-695.	0.9	13
550	Editorial Assessing renal function “ searching for the perfect marker continues!. Archives of Medical Science, 2011, 4, 565-567.	0.4	13
551	Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East. Open Cardiovascular Medicine Journal, 2011, 5, 203-209.	0.6	13
552	The effect of biological age on the metabolic responsiveness of mice fed a high-fat diet. Laboratory Animals, 2013, 47, 241-244.	0.5	13
553	Statins and Infrainguinal Vascular Bypass Procedures. Current Vascular Pharmacology, 2013, 11, 51-57.	0.8	13
554	Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 851-855.	1.5	13
555	Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. Journal of the American College of Nutrition, 2019, 38, 633-639.	1.1	13
556	Rationale for screening selected patients for asymptomatic carotid artery stenosis. Current Medical Research and Opinion, 2020, 36, 361-365.	0.9	13
557	Diabetes and carotid artery disease: a narrative review. Annals of Translational Medicine, 2020, 8, 1280-1280.	0.7	13
558	Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Disease“Pathogenesis and Pharmacological Treatment Options. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 25-39.	1.0	13

#	ARTICLE	IF	CITATIONS
559	Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players. <i>Current Pharmaceutical Design</i> , 2021, 27, 3020-3035.	0.9	13
560	Erythropoietin update 2011. <i>Medical Science Monitor</i> , 2011, 17, RA240-RA247.	0.5	13
561	Effects of Improving Glycemic Control with Insulin on Leptin, Adiponectin, Ghrelin and Neuropeptidey Levels in Patients with Type 2 Diabetes Mellitus: a Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 136-147.	0.6	13
562	Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes. <i>Current Pharmaceutical Design</i> , 2020, 26, 5637-5649.	0.9	13
563	Management of a Patient With a Null Low-Density Lipoprotein Receptor Mutation. <i>Angiology</i> , 2007, 57, 729-732.	0.8	12
564	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 809-820.	1.5	12
565	Assessment of Lower Extremity Peripheral Arterial Disease Using a Novel Automated Optical Device. <i>Vascular and Endovascular Surgery</i> , 2008, 41, 522-527.	0.3	12
566	Aortic stiffness in diabetes mellitus – association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 267-274.	1.5	12
567	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 16-17.	2.9	12
568	Serum Leptin Levels in Patients Undergoing Carotid Endarterectomy: A Pilot Study. <i>Angiology</i> , 2009, 60, 698-704.	0.8	12
569	Editorial: [Statins and Cardiovascular Events in Patients with End-Stage Renal Disease on Hemodialysis. The AURORA Results Suggest the Need for Earlier Intervention]. <i>Current Vascular Pharmacology</i> , 2009, 7, 264-266.	0.8	12
570	ESVS Guidelines: Section B - Diagnosis and Investigation of Patients with Carotid Stenosis. <i>Current Vascular Pharmacology</i> , 2010, 8, 682-691.	0.8	12
571	The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals. <i>Current Pharmaceutical Design</i> , 2010, 16, 3815-3822.	0.9	12
572	Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. <i>Current Medical Research and Opinion</i> , 2011, 27, 879-885.	0.9	12
573	Ideal lipid profile and genes for an extended life span. <i>Current Opinion in Cardiology</i> , 2011, 26, 348-355.	0.8	12
574	Perioperative/Periprocedural Effects of Statin Treatment for Patients Undergoing Vascular Surgery or Endovascular Procedures: An Update. <i>Current Vascular Pharmacology</i> , 2012, 11, 112-120.	0.8	12
575	Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES. <i>Lipids in Health and Disease</i> , 2018, 17, 219.	1.2	12
576	Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. <i>Atherosclerosis</i> , 2019, 284, 129-135.	0.4	12

#	ARTICLE	IF	CITATIONS
577	A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study. <i>British Journal of Nutrition</i> , 2019, 121, 1294-1302.	1.2	12
578	Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2020, 36, 731-740.	0.9	12
579	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2267-2277.	0.9	11
580	Atenolol: Differences in Mode of Action Compared with other Antihypertensives. An Opportunity to Identify Features that Influence Outcome?. <i>Current Pharmaceutical Design</i> , 2007, 13, 229-239.	0.9	11
581	Smoking, Abdominal Aortic Aneurysms, and Ischemic Heart Disease: Is There a Link?. <i>Angiology</i> , 2008, 59, 664-666.	0.8	11
582	Carotid Artery Stenting May Be Losing the Battle against Carotid Endarterectomy for the Management of Symptomatic Carotid Artery Stenosis, But the Jury Is Still Out. <i>Vascular</i> , 2009, 17, 183-189.	0.4	11
583	Statins and venous thromboembolism: a novel effect of statins?. <i>Current Medical Research and Opinion</i> , 2009, 25, 1807-1809.	0.9	11
584	Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?. <i>Current Pharmaceutical Design</i> , 2010, 16, 3839-3847.	0.9	11
585	Undertreatment of hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2010, 26, 439-443.	0.9	11
586	Dyslipidemia Induced by Drugs Used for the Prevention and Treatment of Vascular Diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 85-89.	0.6	11
587	Comparison of Fibrate, Ezetimibe, Low- and High-Dose Statin Therapy for the Dyslipidemia of the Metabolic Syndrome in a Mouse Model. <i>Angiology</i> , 2011, 62, 144-154.	0.8	11
588	Local Versus General Anesthesia for Carotid Endarterectomy. <i>Angiology</i> , 2012, 63, 405-408.	0.8	11
589	Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]. <i>Current Vascular Pharmacology</i> , 2012, 10, 173-177.	0.8	11
590	Statins and nonalcoholic fatty liver disease: a bright future?. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1089-1093.	1.9	11
591	All-cause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used?. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 46-52.	0.9	11
592	Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know. <i>Annals of Translational Medicine</i> , 2020, 8, 1265-1265.	0.7	11
593	Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107619.	1.2	11
594	Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. <i>International Journal of Clinical Practice</i> , 2021, 75, e14833.	0.8	11

#	ARTICLE	IF	CITATIONS
595	Aliskiren, a Direct Renin Inhibitor, in Clinical Practice: A New Approach in the Treatment of Hypertension. <i>Current Vascular Pharmacology</i> , 2010, 8, 344-362.	0.8	11
596	Involvement of Signaling Molecules on Na <sup>+</sup> /H <sup>+</sup> Exchanger-1 Activity in Human Monocytes. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 181-188.	0.6	11
597	Gender and Socio-economic Differences in Daily Smoking and Smoking Cessation Among Adult Residents in a Greek Rural Area. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 15-21.	0.6	11
598	Gender influence on postprandial lipemia in heterozygotes for familial hypercholesterolemia. <i>Annals of Clinical and Laboratory Science</i> , 2007, 37, 335-42.	0.2	11
599	More on PROSPER. <i>Lancet, The</i> , 2003, 361, 1135-1136.	6.3	10
600	Lipid Lowering Therapy in the Elderly: Is there a Benefit?. <i>Current Pharmaceutical Design</i> , 2006, 12, 3945-60.	0.9	10
601	The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3009-3020.	0.9	10
602	Shape of the Nations survey and attitudes to cardiometabolic risk. <i>Current Medical Research and Opinion</i> , 2007, 23, 25-28.	0.9	10
603	Lipid abnormalities and cardiovascular risk in the elderly. <i>Current Medical Research and Opinion</i> , 2008, 24, 653-657.	0.9	10
604	Statins and Heart Failure. <i>Angiology</i> , 2008, 59, 58S-61S.	0.8	10
605	The Role of Trimetazidine After Acute Myocardial Infarction. <i>Current Vascular Pharmacology</i> , 2008, 6, 282-291.	0.8	10
606	Lipid Profile, Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families with a Positive History of Cardiovascular Diseases and/or Hyperlipidemia. <i>Angiology</i> , 2009, 60, 455-461.	0.8	10
607	Na <sup>+</sup> /H <sup>+</sup> -exchanger-1: a link with atherogenesis?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1545-1556.	1.9	10
608	Gender Differences in the Treatment of Ischemic Heart Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 1059-1069.	0.9	10
609	Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 88-97.	0.6	10
610	Statin therapy and new-onset diabetes: an attempt at recommendations. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 213-216.	1.2	10
611	Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , 2015, 31, 191-195.	0.9	10
612	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 241-242.	1.8	10

#	ARTICLE	IF	CITATIONS
613	Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1175-1177.	1.4	10
614	Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism: Clinical and Experimental, 2020, 109, 154305.	1.5	10
615	More Good News on Statins and COVID-19. American Journal of Cardiology, 2021, 138, 127-128.	0.7	10
616	The association between serum uric acid levels and 10-year cardiovascular disease incidence: results from the ATTICA prospective study. Reviews in Cardiovascular Medicine, 2021, 22, 991.	0.5	10
617	Statin Treatment, Carotid Atherosclerotic Plaque Macrophage Infiltration and Circulating Inflammatory Markers. Open Cardiovascular Medicine Journal, 2008, 2, 110-114.	0.6	10
618	The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. Archives of Medical Science, 2012, 8, 970-7.	0.4	10
619	Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): Response to Knopp. Diabetes Care, 2006, 29, 2561-2561.	4.3	9
620	The Relationship Between Circulating Fibrinogen and Lipoprotein (a) Levels in Patients With Primary Dyslipidemia. Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 35-42.	0.7	9
621	Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. Angiology, 2008, 59, 36-46.	0.8	9
622	Effect of Statins on Serum Apolipoprotein J and Paraoxonase-1 Levels in Patients With Ischemic Heart Disease Undergoing Coronary Angiography. Angiology, 2008, 59, 137-144.	0.8	9
623	Effect of Cardiovascular Drugs on Adenosine Deaminase Activity. Angiology, 2008, 59, 740-744.	0.8	9
624	Soluble but Not Platelet P-selectin Correlates With Spontaneous Platelet Aggregation: A Pilot Study. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 227-233.	0.7	9
625	Statins and Heart Failure. Journal of the American College of Cardiology, 2010, 55, 1644-1645.	1.2	9
626	Is the Risk for Cardiovascular Disease Increased in all Phenotypes of the Polycystic Ovary Syndrome?. Angiology, 2011, 62, 285-290.	0.8	9
627	State of the art papers Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. Archives of Medical Science, 2011, 6, 1067-1075.	0.4	9
628	Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease. Digestive Diseases and Sciences, 2012, 57, 1109-1109.	1.1	9
629	Summarizing the FIELD study: lessons from a 'negative' trial. Expert Opinion on Pharmacotherapy, 2013, 14, 2601-2610.	0.9	9
630	The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Current Medical Research and Opinion, 2014, 30, 1701-1705.	0.9	9



#	ARTICLE	IF	CITATIONS
631	In replyâ€”Coenzyme Q10 and Statin-Induced Myopathy. Mayo Clinic Proceedings, 2015, 90, 420-421.	1.4	9
632	Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?. Current Vascular Pharmacology, 2016, 14, 313-315.	0.8	9
633	Reduced Serum Vitamin D Levels Are Associated with Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome. Medicina (Lithuania), 2019, 55, 174.	0.8	9
634	Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study. Clinical Nutrition, 2020, 39, 2730-2733.	2.3	9
635	Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview. Metabolites, 2020, 10, 465.	1.3	9
636	Potato consumption is associated with total and cause-specific mortality: a population-based cohort study and pooling of prospective studies with 98,569 participants. Archives of Medical Science, 2020, 16, 260-272.	0.4	9
637	Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations. Journal of Clinical Medicine, 2020, 9, 170.	1.0	9
638	Hypolipidaemic Drug Treatment: Yesterday is Not Gone Yet, Today is Challenging and Tomorrow is Coming Soon; let us Combine them all. Current Pharmaceutical Design, 2014, 20, 6350-6357.	0.9	9
639	Statins and Type 2 Diabetes Mellitus: An Update After 1 Year. Current Pharmaceutical Design, 2016, 22, 2723-2725.	0.9	9
640	Rectus Sheath Hematoma: A Simplified Emergency Surgical Approach. Open Cardiovascular Medicine Journal, 2011, 5, 4-5.	0.6	9
641	Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGEn2015 studies. Archives of Medical Science, 2020, 18, 604-616.	0.4	9
642	Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?. Anatolian Journal of Cardiology, 2017, 17, 64-65.	0.5	9
643	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGram 2015 Study. Journal of Clinical Medicine, 2021, 10, 5656.	1.0	9
644	Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opinion on Investigational Drugs, 2008, 17, 445-449.	1.9	8
645	JUPITER: major implications for vascular risk assessment. Current Medical Research and Opinion, 2009, 25, 133-137.	0.9	8
646	Proposing a &#x201C;Lipemic Index&#x201D; As a Nutritional and Research Tool. Current Vascular Pharmacology, 2011, 9, 313-317.	0.8	8
647	Postprandial Lipemia in Children and Adolescents. Current Vascular Pharmacology, 2011, 9, 318-320.	0.8	8
648	What is the risk of hyperkalaemia in heart failure?. Expert Opinion on Pharmacotherapy, 2011, 12, 2329-2338.	0.9	8

#	ARTICLE	IF	CITATIONS
649	Relation of Improvement in Glomerular Filtration Rate With Atorvastatin to Reductions in Heart Failure Morbidity. <i>American Journal of Cardiology</i> , 2012, 110, 763.	0.7	8
650	Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk<sup>1</sup>. <i>Clinical Endocrinology</i> , 2012, 76, 177-178.	1.2	8
651	Statins in Patients With Renal Dysfunction. <i>American Journal of Cardiology</i> , 2012, 109, 1537.	0.7	8
652	Editorial (Diabetes, Obesity and Vascular Disease - An Update). <i>Current Pharmaceutical Design</i> , 2013, 19, 4900-4903.	0.9	8
653	Risk of illness, hospitalization and death in a cohort of blood donors in Italy. <i>Current Medical Research and Opinion</i> , 2014, 30, 1803-1812.	0.9	8
654	Subclinical Cushing's syndrome and cardiovascular disease. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 361.	5.5	8
655	Hyperuricaemia in Cardiovascular Diseases: A Passive or an Active Player?. <i>Medical Principles and Practice</i> , 2015, 24, 269-270.	1.1	8
656	High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 9-11.	1.2	8
657	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies " Part 2. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 893-915.	1.0	8
658	Left atrial volume: An independent predictor of cardiovascular outcomes. <i>International Journal of Cardiology</i> , 2018, 265, 234-235.	0.8	8
659	Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results From a Cohort Study. <i>Journal of the American College of Nutrition</i> , 2020, 39, 407-413.	1.1	8
660	Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study. <i>Archives of Medical Science</i> , 2021, 17, 739-751.	0.4	8
661	Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 739-755.	0.8	8
662	Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension. <i>Current Pharmaceutical Design</i> , 2013, 19, 3766-3772.	0.9	8
663	Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 297-301.	0.6	8
664	Atrial fibrillation, inflammation and statins. <i>Hellenic Journal of Cardiology</i> , 2006, 47, 51-3.	0.4	8
665	Letters to the Editor. <i>Angiology</i> , 1999, 50, 959-961.	0.8	7
666	Decreased urinary bladder apoptosis in a rabbit model of diabetes mellitus. <i>Urological Research</i> , 2002, 30, 79-83.	1.5	7

#	ARTICLE	IF	CITATIONS
667	Increased platelet purinergic sensitivity in peripheral arterial disease – A pilot study. <i>Platelets</i> , 2005, 16, 261-267.	1.1	7
668	Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2006, 22, 2037-2039.	0.9	7
669	Statins and Regression of Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 2197.	3.8	7
670	Serotonin Induces a Biphasic Response in Rabbit Cavernosal Smooth Muscle: Relevance to the Erectile Process. <i>Urologia Internationalis</i> , 2007, 79, 255-261.	0.6	7
671	Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]. <i>Current Pharmaceutical Design</i> , 2008, 14, 306-308.	0.9	7
672	CORONA, Statins, and Heart Failure: Who Lost the Crown?. <i>Angiology</i> , 2008, 59, 5-8.	0.8	7
673	Editorial [ Angiogenesis: A Promising Treatment Option for Peripheral Arterial Disease ]. <i>Current Vascular Pharmacology</i> , 2008, 6, 78-80.	0.8	7
674	Acute Limb Ischemia Caused by Femoral Arterial Line Induces Remote Liver Injury in a Rabbit Model of Liver Ischemia/Reperfusion Injury. <i>Angiology</i> , 2009, 60, 554-561.	0.8	7
675	Statin-fibrate combination for mixed dyslipidaemia: a limited option?. <i>Current Medical Research and Opinion</i> , 2010, 26, 2137-2140.	0.9	7
676	To switch (statins) or not to switch? That is the question. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2943-2946.	0.9	7
677	Screening for peripheral artery disease in dialysis patients: an opportunity for early disease detection and timely initiation of appropriate therapeutic measures. <i>International Urology and Nephrology</i> , 2011, 43, 143-145.	0.6	7
678	Passive Smoking: The Democratic Right of Nonsmokers to Survive. <i>Angiology</i> , 2011, 62, 520-522.	0.8	7
679	Effect of Antiplatelet Agents, Statins, and Other Drugs on Vascular Access Patency Rates. <i>Angiology</i> , 2012, 63, 5-8.	0.8	7
680	Statins and Venous Thromboembolism. <i>Angiology</i> , 2013, 64, 489-491.	0.8	7
681	Editorial: Statin Potency, LDL Receptors and New Onset Diabetes. <i>Current Vascular Pharmacology</i> , 2014, 12, 739-740.	0.8	7
682	Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality?. <i>Archives of Medical Science</i> , 2015, 1, 230-231.	0.4	7
683	Impact of comorbidity on outcome in kidney transplant recipients: a retrospective study in Italy. <i>Internal and Emergency Medicine</i> , 2016, 11, 825-832.	1.0	7
684	The impact of metabolic syndrome and its components on perioperative outcomes after elective laparotomy - A prospective observational study. <i>American Journal of Surgery</i> , 2017, 214, 831-837.	0.9	7

#	ARTICLE	IF	CITATIONS
685	Carotid Bifurcation Geometry as Assessed by Ultrasound is Associated with Early Carotid Atherosclerosis. <i>Annals of Vascular Surgery</i> , 2018, 51, 207-216.	0.4	7
686	Dyslipidaemia in the elderly: to treat or not to treat?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 259-278.	1.3	7
687	Appropriate Patient Selection for Carotid Revascularization Procedures is Urgently Needed. <i>Angiology</i> , 2018, 69, 12-16.	0.8	7
688	Excessive "orthotopic" fat accumulation: Links with cardiometabolic diseases and potential drug treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 6321-6322.	2.0	7
689	Update on Cilostazol: A Critical Review of its Antithrombotic and Cardiovascular Actions and its Clinical Applications. <i>Journal of Clinical Pharmacology</i> , 2021, , .	1.0	7
690	Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 41-47.	1.6	7
691	Muscarinic stimulation of prostanoid synthesis by the isolated rat trachea: calcium dependency and effect of cortisol and cigarette smoke. <i>European Journal of Pharmacology</i> , 1989, 160, 107-115.	1.7	6
692	Î³-Glutamyltransferase and Vascular Disease. <i>Clinical Chemistry</i> , 2003, 49, 522-523.	1.5	6
693	Clopidogrel and vascular disease prevention. <i>Current Medical Research and Opinion</i> , 2004, 20, 1835-1838.	0.9	6
694	Mean platelet volume in patients with type 2 diabetes mellitus. <i>Platelets</i> , 2005, 16, 219-220.	1.1	6
695	Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1437-1440.	0.9	6
696	Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]. <i>Current Vascular Pharmacology</i> , 2008, 6, 81-83.	0.8	6
697	Anaesthetic techniques for carotid surgery. <i>Lancet, The</i> , 2009, 373, 807.	6.3	6
698	Statin use in patients with chronic kidney disease stages 2-4: targeting beyond improved mortality rates. <i>International Urology and Nephrology</i> , 2010, 42, 711-713.	0.6	6
699	Oxidative Stress in the Pathogenesis of Abdominal Aortic Aneurysms: A Possible Pathway for the Effect of Statins?. <i>Angiology</i> , 2010, 61, 226-227.	0.8	6
700	The Impact of Impaired Renal Function on Long-Term Outcomes in Patients With Peripheral Arterial Disease. <i>Angiology</i> , 2010, 61, 415-416.	0.8	6
701	Statins may not prevent structural valve degeneration of aortic bioprosthetic valves, but should probably be prescribed to patients undergoing heart valve surgery nonetheless. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2010, 11, 302-302.	0.5	6
702	Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 253-257.	1.2	6

#	ARTICLE	IF	CITATIONS
703	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 1347-1353.	1.5	6
704	Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?. <i>Current Medical Research and Opinion</i> , 2011, 27, 7-11.	0.9	6
705	Peripheral Arterial Disease and HIV-Positive Patients. <i>Angiology</i> , 2011, 62, 7-9.	0.8	6
706	Smoking and non-alcoholic steatohepatitis (NASH): The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. <i>Journal of Hepatology</i> , 2012, 57, 476.	1.8	6
707	State of the art paper The role of G protein coupled receptor kinases in neurocardiovascular pathophysiology. <i>Archives of Medical Science</i> , 2012, 6, 970-977.	0.4	6
708	Mean platelet volume in patients undergoing percutaneous coronary intervention. <i>Platelets</i> , 2015, 26, 269-270.	1.1	6
709	Platelets and diabetes: A complex association. <i>Platelets</i> , 2015, 26, 267-268.	1.1	6
710	Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e1-e2.	1.5	6
711	Editorial: Lipoprotein (a), More than Just Cholesterol?. <i>Current Medicinal Chemistry</i> , 2017, 24, 952-956.	1.2	6
712	More on carotid atherosclerosis and ezetimibe. <i>International Angiology</i> , 2017, 36, 580-581.	0.4	6
713	Iron absorption, bone marrow fat and hematopoiesis in heart failure: Additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107408.	1.2	6
714	Management of patients with type 2 diabetes mellitus and acute coronary syndrome: Better be safe than sorry!. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 465-467.	1.2	6
715	Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 1. <i>Current Vascular Pharmacology</i> , 2022, 20, 3-15.	0.8	6
716	The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 48-50.	0.6	6
717	Weekend Versus Weekday, Morning Versus Evening Admission in Relationship to Mortality in Acute Coronary Syndrome Patients in 6 Middle Eastern Countries: Results from Gulf Race 2 Registry. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 106-112.	0.6	6
718	Alice through the Looking-glass: Can We Improve Peer Review?. <i>International Journal of Lower Extremity Wounds</i> , 2022, , 153473462210847.	0.6	6
719	Differential Alterations of Spontaneous and Stimulated $^{45}\text{Ca}^{2+}$ Uptake by Platelets from Patients with Type I and Type II Diabetes Mellitus. <i>Journal of Diabetes and Its Complications</i> , 1999, 13, 271-276.	1.2	5
720	The Molecular Basis of Penile Erection. <i>Current Medical Research and Opinion</i> , 2000, 16, s21-s30.	0.9	5

#	ARTICLE	IF	CITATIONS
721	Sildenafil: a Urologist's View. <i>Current Medical Research and Opinion</i> , 2000, 16, s48-s58.	0.9	5
722	Natural Statins and Stroke. <i>Circulation</i> , 2000, 101, E45.	1.6	5
723	Platelet Activation in Bypass Surgery for Critical Limb Ischemia. <i>Vascular and Endovascular Surgery</i> , 2007, 41, 322-329.	0.3	5
724	Obesity and postoperative atrial fibrillation. Is there no connection?. <i>American Heart Journal</i> , 2008, 156, e5.	1.2	5
725	Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1777-1779.	1.9	5
726	Kidney Function and Estimated Vascular Risk in Patients with Primary Dyslipidemia. <i>Open Cardiovascular Medicine Journal</i> , 2009, 3, 57-68.	0.6	5
727	Irradiation-Induced Carotid Artery Stenosis: A Preventable Complication of Neck Radiotherapy?. <i>Angiology</i> , 2009, 60, 273-275.	0.8	5
728	Is High-sensitivity C-reactive Protein Associated with Subclinical Peripheral Atherosclerosis?. <i>Angiology</i> , 2009, 60, 8-11.	0.8	5
729	Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients with Stable Angina. <i>Angiology</i> , 2009, 60, 322-328.	0.8	5
730	Bilirubin and peripheral arterial disease: 15 years later. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 139-140.	1.5	5
731	Endovascular Abdominal Aortic Aneurysm Repair (EVAR) Procedures: Counterbalancing the Benefits With the Costs. <i>Vascular and Endovascular Surgery</i> , 2010, 44, 319-320.	0.3	5
732	Severe, But Not Moderate, Carotid Atherosclerosis May Predict Concomitant Vascular Disease in Other Arterial Beds. <i>Stroke</i> , 2010, 41, e597; author reply e598.	1.0	5
733	Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal. <i>Clinical Biochemistry</i> , 2011, 44, 237-244.	0.8	5
734	The DEFINE study: a bright future for CETP inhibitors?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 311-314.	1.9	5
735	A New Rapid Method to Measure Human Platelet Cholesterol. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 578-584.	0.7	5
736	Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 287-288.	0.9	5
737	Therapeutic options for statin-intolerant patients. <i>Current Medical Research and Opinion</i> , 2012, 28, 345-349.	0.9	5
738	Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012, 17, 427-427.	1.0	5

#	ARTICLE	IF	CITATIONS
739	Ezetimibe â€“ a new approach in hypercholesterolemia management. <i>Pharmacological Reports</i> , 2012, 64, 997-998.	1.5	5
740	Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. <i>Current Medical Research and Opinion</i> , 2012, 28, 1415-1419.	0.9	5
741	Should we consider ezetimibe to reach even lower LDL-C targets?. <i>Current Medical Research and Opinion</i> , 2015, 31, 459-460.	0.9	5
742	Does bilirubin protect against developing diabetes mellitus?. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 728-737.	1.2	5
743	Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1-3.	1.2	5
744	Editorial: Natural Products as the Integral Part of the Therapy?. <i>Current Pharmaceutical Design</i> , 2017, 23, 2411-2413.	0.9	5
745	Lipids: a personal view of the past decade. <i>Hormones</i> , 2018, 17, 461-478.	0.9	5
746	The Association Between Abdominal Aortic Aneurysms With Cardiovascular and Noncardiovascular Diseases. <i>Angiology</i> , 2019, 70, 8-11.	0.8	5
747	Low-carbohydrate diet: forget restriction, replace with balance!. <i>European Heart Journal</i> , 2020, 41, 1058-1058.	1.0	5
748	Management of patients with asymptomatic carotid stenosis may need to be individualized: a multidisciplinary call for action. Republication of <i>J Stroke</i> 2021;23:202-212. <i>International Angiology</i> , 2021, 40, 487-496.	0.4	5
749	Increased Fluorodeoxyglucose Uptake Following Endovascular Abdominal Aortic Aneurysm Repair: A Predictor of Endoleak?. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 117-119.	0.6	5
750	Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters. <i>Open Cardiovascular Medicine Journal</i> , 2012, 6, 122-125.	0.6	5
751	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. <i>Rheumatology International</i> , 2022, 42, 261-271.	1.5	5
752	Statins and diabetes mellitus progression: a fly in the ointment?. <i>Nature Reviews Endocrinology</i> , 2022, 18, 137-138.	4.3	5
753	Endothelin-1 and Urinary Bladder Hyperplasia Following Partial Bladder Outlet Obstruction. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S262-S263.	0.8	4
754	New-onset diabetes after transplantation. <i>Lancet, The</i> , 2005, 365, 1766.	6.3	4
755	Mortality after First Myocardial Infarction in Greek Patients: A 4-Year Follow-Up Study. <i>Angiology</i> , 2009, 60, 582-587.	0.8	4
756	Effect of Statins on Renal Function in Patients With Peripheral Arterial Disease. <i>Vascular and Endovascular Surgery</i> , 2009, 42, 620-621.	0.3	4



#	ARTICLE	IF	CITATIONS
757	Erectile dysfunction: a warning sign of silent vascular disease. <i>International Urology and Nephrology</i> , 2009, 41, 909-911.	0.6	4
758	Chronic Hepatitis C, Insulin Resistance and Vascular Disease. <i>Current Pharmaceutical Design</i> , 2010, 16, 3823-3829.	0.9	4
759	Are Symptomatic Patients Appropriate Candidates For Carotid Artery Stenting? No (at Least Not At) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	0.4	4
760	Statins and contrast-induced nephropathy: Issues requiring further investigation. <i>International Journal of Cardiology</i> , 2011, 151, 364.	0.8	4
761	Impact of Statins on Glucose Metabolismâ€”A Matter of Debate. <i>American Journal of Cardiology</i> , 2011, 107, 1866.	0.7	4
762	Why the US Center for Medicare and Medicaid Services Should Not Extend Reimbursement Indications for Carotid Artery Angioplasty/Stenting. <i>Angiology</i> , 2012, 63, 639-644.	0.8	4
763	Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Brain and Behavior</i> , 2012, 2, 200-207.	1.0	4
764	Angiotensin II Increases Corpus Cavernosal Contractility and Oxidative Stress in Partial Bladder Outlet Obstructed Rabbits: Relevance to Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2013, 10, 1251-1258.	0.3	4
765	Statins: A sine qua non of the management of patients with abdominal aortic aneurysms. <i>International Journal of Cardiology</i> , 2013, 168, 4528.	0.8	4
766	Response to Red Blood Cell Distribution Width Is a Predictor of Readmission in Cardiac Patients. <i>Clinical Cardiology</i> , 2013, 36, 364-365.	0.7	4
767	Regarding â€œProgression of asymptomatic carotid stenosis despite optimal medical therapyâ€. <i>Journal of Vascular Surgery</i> , 2014, 59, 1752-1753.	0.6	4
768	A possible relationship between renal impairment and complications development in type 2 diabetes mellitus: a prospective, observational study in Italy. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 771-775.	1.2	4
769	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	0.9	4
770	Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. <i>Pharmacological Research</i> , 2017, 124, 64-73.	3.1	4
771	Endocan and Erectile Dysfunction. <i>American Journal of Men's Health</i> , 2019, 13, 155798831989388.	0.7	4
772	Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 2. <i>Current Vascular Pharmacology</i> , 2022, 20, 16-26.	0.8	4
773	Narrative Review of Carotid disease and the kidney. <i>Annals of Translational Medicine</i> , 2021, 9, 1210-1210.	0.7	4
774	Acute and long-term antiplatelet therapy. <i>Drugs of Today</i> , 2008, 44, 331.	0.7	4

#	ARTICLE	IF	CITATIONS
775	Abnormal Peri-organ-Intra-organ Fat (APIFat) and Rheumatoid Arthritis: An Under-investigated Link for Increased Cardiovascular Risk?. <i>Current Vascular Pharmacology</i> , 2020, 18, 249-253.	0.8	4
776	The effect of alcohol and gemfibrozil co-administration in Wistar rats. <i>In Vivo</i> , 2004, 18, 49-53.	0.6	4
777	Comparison of Recent Practice Guidelines for the Management of Patients With Asymptomatic Carotid Stenosis. <i>Angiology</i> , 2022, 73, 903-910.	0.8	4
778	Reduction of endothelin-1 binding and inhibition of endothelin-1-mediated detrusor contraction by naftidrofuryl. <i>Clinical Science</i> , 2002, 103, 459S-463S.	1.8	3
779	Erectile dysfunction: a need for greater awareness. <i>Perspectives in Public Health</i> , 2004, 124, 214-216.	0.5	3
780	Effects of Simvastatin Alone Versus Fenofibrate Alone Versus Simvastatin Plus Fenofibrate on Lipoprotein Subparticle Profiles in Patients With Diabetes Mellitus and Mixed Dyslipidemia. <i>American Journal of Cardiology</i> , 2008, 101, 1679-1680.	0.7	3
781	The Peripheral Serotonergic Pathway: A New Target for Treating Erectile Dysfunction?. <i>American Journal of Men's Health</i> , 2008, 2, 37-39.	0.7	3
782	A Comparison of the Aldosterone-Blocking Agents Eplerenone and Spironolactone. <i>Clinical Cardiology</i> , 2009, 32, 230-230.	0.7	3
783	Editorial [Concurrent Blood Pressure, Glycemic and Lipid Control for the Prevention of Vascular Complications of Type II Diabetes Mellitus: A Long Overdue Objective?]. <i>Current Vascular Pharmacology</i> , 2010, 8, 1-4.	0.8	3
784	Interpreting the Carotid Revascularization Endarterectomy Versus Stent Trial (CREST): Additional Trials Are Needed. <i>Vascular</i> , 2010, 18, 247-249.	0.4	3
785	Predictors of Abdominal Aortic Aneurysm (AAA) Growth and AAA Rupture Risk Besides AAA Size: Fact or Fiction?. <i>Angiology</i> , 2010, 61, 321-323.	0.8	3
786	Best medical treatment for a symptomatic carotid artery stenosis. <i>Lancet, The</i> , 2011, 377, 123.	6.3	3
787	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. <i>Future Cardiology</i> , 2012, 8, 813-817.	0.5	3
788	Lipids and Non-Cardiac Vascular Disease: A Lecture Overview. <i>Current Vascular Pharmacology</i> , 2012, 10, 743-744.	0.8	3
789	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. <i>Journal of Clinical Lipidology</i> , 2012, 6, 93.	0.6	3
790	Editorial The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. <i>Archives of Medical Science</i> , 2012, 1, 6-10.	0.4	3
791	Peripheral artery disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 912.	1.2	3
792	Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 471-472.	0.9	3

#	ARTICLE	IF	CITATIONS
793	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. <i>Atherosclerosis</i> , 2015, 238, 182-184.	0.4	3
794	Statins induce regression of carotid artery stenosis: Fact or fiction?. <i>International Journal of Cardiology</i> , 2016, 220, 680.	0.8	3
795	Critical Issues and Controversies in the Management of Patients With Carotid Artery Stenosis. <i>Angiology</i> , 2016, 67, 405-407.	0.8	3
796	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G681-G682.	1.6	3
797	Fetal/Infant Origins of Adult Vascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 18, 418-420.	0.8	3
798	Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 51-58.	1.0	3
799	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) <i>Tj ETQqb.B0.7843i14 rgBT</i>	0.8	3
800	Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2021, 19, 469-486.	0.8	3
801	Effect of Metformin on Plasma Fibrinogen Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Current Pharmaceutical Design</i> , 2018, 24, 1034-1040.	0.9	3
802	The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2010, 999, 1-13.	0.8	3
803	Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement. <i>Current Vascular Pharmacology</i> , 2011, 999, 1-13.	0.8	3
804	Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study. <i>Clinical Nutrition</i> , 2020, 39, 3730-3735.	2.3	3
805	Early statin therapy in patients with acute coronary syndrome. <i>Hellenic Journal of Cardiology</i> , 2005, 46, 5-8.	0.4	3
806	Modifying cardiovascular risk factors: newer insights and preventive measures. <i>Current Pharmaceutical Design</i> , 2009, 15, 1034-7.	0.9	3
807	Measurement of atherosclerosis progression. <i>Lancet, The</i> , 2001, 358, 329-330.	6.3	2
808	Ciprofibrate Versus Gemfibrozil in the Treatment of Mixed Hyperlipidemias: An Open-Label, Multicenter Study. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 1385-1386.	1.5	2
809	The Effect of Clopidogrel (Plavix) on Platelet Function in Patients with Peripheral Vascular Disease â€• Comparison with Aspirin. <i>Journal of Cardiac Surgery</i> , 2002, 17, 563-563.	0.3	2
810	RE: THE PREVALENCE OF HYPERTENSION, HYPERLIPIDEMIA, DIABETES MELLITUS AND DEPRESSION IN MEN WITH ERECTILE DYSFUNCTION. <i>Journal of Urology</i> , 2005, 173, 1050-1050.	0.2	2

#	ARTICLE	IF	CITATIONS
811	Exorcising Ghosts and Unwelcome Guests. <i>Annals of Internal Medicine</i> , 2006, 144, 149.	2.0	2
812	Heparin Therapy Leads to Platelet Activation and Prolongation of Platelet Function Analyser-100 Closure Time. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 156-157.	1.0	2
813	Additional Effects of Statins in Surgical Patients. <i>Annals of Surgery</i> , 2008, 248, 140-141.	2.1	2
814	The Impact of Novel Treatment Modalities on the Therapeutic Approach of Cardiovascular Diseases. <i>Angiology</i> , 2009, 60, 5-7.	0.8	2
815	Aortic Pulse Wave Velocity May Have Prognostic Value Not Just for Hypertension but Also for Abdominal Aortic Aneurysms. <i>Hypertension</i> , 2010, 55, e22; author reply e23.	1.3	2
816	Endovascular Versus Open Repair of Abdominal Aortic Aneurysms: Interpreting the Landmark United Kingdom EVAR 1 Results. <i>Journal of Endovascular Therapy</i> , 2010, 17, 599-601.	0.8	2
817	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial: Comment on Ruggenenti et al.. <i>Diabetes Care</i> , 2010, 33, e132-e132.	4.3	2
818	Alanine Aminotransferase Is Associated With Metabolic Syndrome Independently of Insulin Resistance. <i>Circulation Journal</i> , 2011, 75, 2027.	0.7	2
819	Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan. <i>Clinical Therapeutics</i> , 2011, 33, 2091.	1.1	2
820	Current treatment for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2141-2142.	0.9	2
821	Does Metabolic Syndrome Influence Outcome Following Percutaneous Coronary Intervention?. <i>Angiology</i> , 2011, 62, 437-439.	0.8	2
822	Why the United States Center for Medicare and Medicaid Services should not extend reimbursement indications for carotid artery angioplasty/stenting. <i>Vascular</i> , 2012, 20, 1-7.	0.4	2
823	Hypertriglyceridemia-induced acute pancreatitis: clinical considerations. <i>Clinical Lipidology</i> , 2012, 7, 259-262.	0.4	2
824	Response to Mildly Decreased Glomerular Filtration Rate Is Associated With Poor Coronary Heart Disease Outcome. <i>Clinical Cardiology</i> , 2012, 35, 315-315.	0.7	2
825	Renal dysfunction and all-cause mortality in cardio-renal syndrome: Calculation of glomerular filtration rate is crucial, independent of the equation. <i>International Journal of Cardiology</i> , 2013, 170, e11-e13.	0.8	2
826	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>Journal of Clinical Lipidology</i> , 2013, 7, 88.	0.6	2
827	Additional Issues on Screening, Prevention, and Treatment of Abdominal Aortic Aneurysms. <i>American Journal of Men's Health</i> , 2013, 7, 472-474.	0.7	2
828	<sup>18</sup> F-Fluorodeoxyglucose Uptake in Abdominal Aortic Aneurysms: A Useful Biomarker of AAA Rupture Risk. <i>BioMed Research International</i> , 2014, 2014, 1-2.	0.9	2

#	ARTICLE	IF	CITATIONS
829	Editorial (Thematic Issue: Novel Data on the Pathogenesis of Atherosclerosis, Treatment Targets, and) Tj ETQq1 1 0.784314 rgBT /Ove Design, 2014, 20, 6215-6219.	0.9	2
830	Caloric and fat intake in statin users. Nature Reviews Endocrinology, 2014, 10, 450-451.	4.3	2
831	Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?). Current Medicinal Chemistry, 2015, 22, 3552-3554.	1.2	2
832	Statins and Niacin: The End of Residual Risk Therapy?. , 2015, , 37-43.		2
833	Can the effects of gender, menopause and ageing on lipid levels be differentiated?. Clinical Endocrinology, 2016, 85, 694-695.	1.2	2
834	Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684â€“1692. Diabetes Care, 2017, 40, e46-e46.	4.3	2
835	Time for new low density lipoprotein cholesterol (LDL-C) targets?. Expert Opinion on Pharmacotherapy, 2017, 18, 1539-1541.	0.9	2
836	Statin use in patients with diabetes: one drug, multiple benefits. Expert Review of Cardiovascular Therapy, 2019, 17, 839-840.	0.6	2
837	Half a century and more of PhD theses by published papers. Scientometrics, 2020, 125, 813-816.	1.6	2
838	NAFLD and Statins. Digestive Diseases and Sciences, 2020, 65, 3052-3053.	1.1	2
839	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.4	2
840	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. Journal of Clinical Medicine, 2021, 10, 4472.	1.0	2
841	The Effect of Graded Systemic Hypoxaemia on Hepatic Tissue Oxygenation. Advances in Experimental Medicine and Biology, 2003, 540, 317-323.	0.8	2
842	Low HDL Cholesterol, Smoking and IL-13 R130Q Polymorphism are Associated with Myocardial Infarction in Greek Cypriot Males. A Pilot Study. Open Cardiovascular Medicine Journal, 2008, 2, 52-59.	0.6	2
843	The burden of carotid-related strokes. Annals of Translational Medicine, 2022, 10, 159-159.	0.7	2
844	Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).. Archives of Medical Science, 2022, , .	0.4	2
845	Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism: Clinical and Experimental, 2022, 132, 155211.	1.5	2
846	A Call to Encourage Participation in the Reviewing Process: The REFEREE Acrostic. International Journal of Lower Extremity Wounds, 2022, , 153473462211026.	0.6	2

#	ARTICLE	IF	CITATIONS
847	Triacylglycerol lowering properties of the adenosine analog GR 79236 during 5 days of dosing large, old rats: A pilot study. Nutrition Research, 1996, 16, 1925-1932.	1.3	1
848	Letter to the Editor. Angiology, 2002, 53, 243-243.	0.8	1
849	Effect of Clopidogrel on Platelet Aggregation and Plasma Concentration of Fibrinogen in Subjects With Cerebral or Coronary Atherosclerotic Disease. Clinical and Applied Thrombosis/Hemostasis, 2002, 8, 381-382.	0.7	1
850	Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. Current Vascular Pharmacology, 2007, 5, 173-174.	0.8	1
851	Sodium-Lithium Countertransport Activity in Healthy, Dyslipidemic, and Hypertensive Individuals. Angiology, 2008, 59, 727-735.	0.8	1
852	Arteriovenous Fistula Leading to Severe Tortuosity and Aneurysm Formation. Journal of Cardiac Surgery, 2009, 24, 109-109.	0.3	1
853	Effects of l-Canavanine and ozone on vascular reactivity in septicemic rats. Journal of Physiology and Biochemistry, 2010, 66, 255-264.	1.3	1
854	eComment: Endovascular repair of ruptured abdominal aortic aneurysms: identifying issues which may be difficult to achieve. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 619-619.	0.5	1
855	874 THE REGULATION OF ANGIOTENSIN II-INDUCED CONTRACTION AND NON ADRENERGIC-NON CHOLINERGIC NEUROTRANSMISSION IN HUMAN CORPUS CAVERNOSAL TISSUE: A ROLE FOR LOSARTAN. Journal of Urology, 2010, 183, .	0.2	1
856	Raised liver enzymes in patients taking statins â€œ Authors' reply. Lancet, The, 2011, 377, 1075-1076.	6.3	1
857	Letter by Paraskevas et al Regarding Article, â€œGuidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Associationâ€• Stroke, 2011, 42, e387.	1.0	1
858	Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice. Oman Medical Journal, 2012, 27, 260-260.	0.3	1
859	Regarding â€œEstimating the risk of solid organ malignancy in patients undergoing routine computed tomography scans after endovascular aneurysm repairâ€• Journal of Vascular Surgery, 2012, 56, 1829.	0.6	1
860	Statins and Infrainguinal Vascular Bypass Procedures. Current Vascular Pharmacology, 2012, 11, 51-57.	0.8	1
861	Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]. Current Vascular Pharmacology, 2012, 10, 745-747.	0.8	1
862	Alcohol consumption and the heart. International Journal of Cardiology, 2013, 168, 4319.	0.8	1
863	Editorial (Thematic Issues: Managing the Cardiovascular Risk Associated with the Metabolic) Tj ETQq1 1 0.784314 ggBT /Overlock 10 Tf 0.9	0.9	1
864	Drug Evaluation: The Combination of Fenofibrate and Simvastatin for the Treatment of Dyslipidemia: When and for Whom?. , 2015, , 179-190.		1

#	ARTICLE	IF	CITATIONS
865	Critical Issues and Controversies in Carotid Artery Stenosis. <i>Angiology</i> , 2016, 67, 789-790.	0.8	1
866	C-reactive protein levels and aortic aneurysmal disease progression after endovascular repair: The jury is still out. <i>International Journal of Cardiology</i> , 2016, 203, 1141.	0.8	1
867	Response letter: Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , 2017, 66, e6.	1.5	1
868	Depression in cardiac and non-cardiac vascular diseases: Current evidence and future perspectives. <i>International Journal of Cardiology</i> , 2018, 271, 21-22.	0.8	1
869	CETP inhibition in the REVEAL trial: could we aim higher?. <i>Archives of Medical Science</i> , 2020, 16, 1229-1230.	0.4	1
870	Editorial: The year in hyperlipidaemia. <i>Current Opinion in Cardiology</i> , 2021, 36, 461.	0.8	1
871	The effect of statins on semen parameters in patients with hypercholesterolemia: A systematic review. <i>Andrology</i> , 2021, 9, 1504-1511.	1.9	1
872	Adherence to statin treatment: an important issue in clinical practice. <i>Current Medical Research and Opinion</i> , 2016, 32, 1639-1640.	0.9	1
873	Letter to Editor: Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. <i>Oman Medical Journal</i> , 2012, 27, 177-177.	0.3	1
874	Incidence of contrast-induced acute kidney injury in patients with acute mesenteric ischemia and identification of potential predictive factors. <i>Vascular</i> , 2021, , 170853812110507.	0.4	1
875	Statins and Fibrates: Should They Be Recommended?., 2015, , 11-23.		1
876	Obstructive sleep apnea and cardiovascular disease: Is mean platelet volume one of the links?. <i>Anatolian Journal of Cardiology</i> , 2016, 16, 223.	0.5	1
877	The Heart Outcomes Prevention Evaluation (HOPE)-3 trial: where do we stand?. <i>Current Opinion in Lipidology</i> , 2017, 28, 88-89.	1.2	1
878	Perivascular adipose tissue in cardiovascular diseases. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 58.	0.5	1
879	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. <i>Archives of Medical Science</i> , 2021, , .	0.4	1
880	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. <i>Biomarker Insights</i> , 2022, 17, 117727192110667.	1.0	1
881	Statin use and renal function after aortic aneurysm repair procedures. <i>Journal of Vascular Surgery</i> , 2021, 74, 2121-2122.	0.6	1
882	Optimal management of asymptomatic carotid stenosis in 2021: the jury is still out. An international, multispecialty, expert review and position statement. <i>International Angiology</i> , 2022, 41, .	0.4	1



#	ARTICLE	IF	CITATIONS
883	Unstable angina. American Heart Journal, 1996, 131, 1234-1235.	1.2	0
884	Altered Cavernosal Endothelin-B-Receptor Binding Sites in the Rabbit Model of Partial Bladder Outlet Obstruction. Journal of Cardiovascular Pharmacology, 2000, 36, S260-S261.	0.8	0
885	The Treatment of Coronary Heart Disease: An Update Part 5: Selected Comments and Questions Compiled by. Current Medical Research and Opinion, 2001, 17, 41-42.	0.9	0
886	In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. BJU International, 2005, 96, 1424-1424.	1.3	0
887	Editorial [Hot Topic: Biochemical and Clinical Relevance of Hyperuricaemia (Executive Editor: Dimitri) Tj ETQq1 1 0.784314 rgBT /Over 4115-4116.	0.9	0
888	Longitudinal Effects of Fenfluramineâ€”Phentermine Use. Angiology, 2007, 58, 772-773.	0.8	0
889	¿QuÃ© papel desempeÃ±a la diabetes mellitus en las tasas de reestenosis y permeabilidad tras la revascularizaciÃ³n infrainginal? RevisiÃ³n crÃ©tica. Annals of Vascular Surgery, 2008, 22, 525-536.	0.0	0
890	MODULATION OF NITRIC OXIDE-MEDIATED RABBIT CORPUS CAVERNOSAL SMOOTH MUSCLE RELAXATION WITH ANGIOTENSIN II: RELEVANCE TO PENILE ERECTION. Journal of Urology, 2008, 179, 337-337.	0.2	0
891	Le diabÃ©te joue-t-il un rÃ´le dans les restÃ©nosies et les taux de permÃ©abilitÃ© aprÃ©s revascularisation artÃ©rielle des membres infÃ©rieurs ? une Ã©tude gÃ©nÃ©rale critique. Annales De Chirurgie Vasculaire, 2008, 22, 521-532.	0.0	0
892	Deterioro de la funciÃ³n renal en la arteriopatÃ­a perifÃ©rica: un parÃ¡metro que no debe ser infravalorado. Annals of Vascular Surgery, 2009, 23, 759-769.	0.0	0
893	L'insuffisance rÃ©nale dans la maladie artÃ©rielle pÃ©riphÃ©rique : Un paramÃ©tre important qui ne devrait pas Ãªtre nÃ©gligÃ©. Annales De Chirurgie Vasculaire, 2009, 23, 749-759.	0.0	0
894	Trials by Independent Expert Bodies. Archives of Internal Medicine, 2010, 170, 2042.	4.3	0
895	The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients. Current Medical Research and Opinion, 2011, 27, 1961-1961.	0.9	0
896	1131 IN-VITRO STUDIES INVESTIGATING THE ROLE OF PERIPHERAL SEROTONERGIC PATHWAY ON THE NORMAL AND DIABETIC HUMAN ERECTILE PROCESS. Journal of Urology, 2011, 185, .	0.2	0
897	Carotid artery stenting may be contraindicated in female patients with symptomatic carotid artery stenosis. Journal of Vascular Surgery, 2011, 54, 1870-1871.	0.6	0
898	Carotid Artery Stenosis and Heart Valve Surgery: A Complex Scenario. Angiology, 2011, 62, 597-600.	0.8	0
899	Fibrinogen, Hematocrit, and Platelets in Mild Kidney Dysfunction and the Role of Uric Acid: An Italian Male Population Study. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 113-114.	0.7	0
900	Carotid artery stenting: â€œGood newsâ€ or â€œbad newsâ€ for post-procedural cognitive function?. International Journal of Cardiology, 2012, 157, 156.	0.8	0

#	ARTICLE	IF	CITATIONS
901	Heparin and platelet activation. <i>Thrombosis Research</i> , 2012, 130, 685.	0.8	0
902	Comment to "Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\alpha$ -lowering property". <i>Digestive and Liver Disease</i> , 2013, 45, 82-83.	0.4	0
903	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. <i>Clinical Lipidology</i> , 2013, 8, 509-512.	0.4	0
904	Platelet cholesterol: From man to seal. <i>Platelets</i> , 2013, 24, 253-254.	1.1	0
905	Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Tj ETQq1 1 0.784314 rgBT/Overlook	0.9	0
906	Reaching hypertriglyceridemia goals. <i>Current Medical Research and Opinion</i> , 2014, 30, 391-393.	0.9	0
907	The Effects of Anti-Diabetic Drugs on LDL Subclasses: Any Role for Colesevelam?. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 205-207.	1.3	0
908	Implications of the timely diagnosis of lower extremity peripheral arterial disease. <i>International Journal of Cardiology</i> , 2014, 173, 551.	0.8	0
909	Do We Need Guideline-Driven Specific Lipid Goals to Achieve Regression of Coronary Atherosclerosis and Maximize Therapy Benefits?. <i>American Journal of Cardiology</i> , 2015, 115, 280.	0.7	0
910	Editorial: Your VISION Will Become Clear Only When You Look Into Your Heart. <i>Current Vascular Pharmacology</i> , 2016, 14, 319-320.	0.8	0
911	Statins, renal function and homocysteine. <i>Pharmacological Reports</i> , 2016, 68, 1093.	1.5	0
912	Coronary Artery Bypass Grafting Combined with Open Versus Endovascular Abdominal Aortic Aneurysm Repair. <i>Annals of Vascular Surgery</i> , 2016, 33, 263-264.	0.4	0
913	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2018, , 189-200.		0
914	Carotid Artery Stenting Has a Role in the Management of Asymptomatic Carotid Stenosis, but This Is Currently Small. <i>Angiology</i> , 2018, 69, 640-641.	0.8	0
915	Statins and substantially increased <sc>ALT</sc> values at baseline. <i>Cardiovascular Therapeutics</i> , 2018, 36, e12444.	1.1	0
916	Prehypertension, the Risk of Hypertension and Events. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 37-55.	0.1	0
917	Vascular surgical procedures in patients with familial hypercholesterolaemia: is it too late?. <i>Current Medical Research and Opinion</i> , 2020, 36, 1255-1255.	0.9	0
918	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2006, , 133-140.		0

#	ARTICLE	IF	CITATIONS
919	Cardiovascular Risk Factors and Peripheral Arterial Disease. , 2010, , 165-172.		0
920	Cardiovascular effects of laparoscopic sleeve gastrectomy. Turk Kardiyoloji Dernegi Arsivi, 2019, 47, 159-161.	0.6	0
921	Comment on "Long-term Prognosis After Elective Abdominal Aortic Aneurysm Repair is Poor in Women and Men: The Challenges Remain"; Annals of Surgery, 2021, 274, e857-e858.	2.1	0
922	Endocrine Disease as a Cause of Cardiovascular Disease: Current Perspectives. Current Pharmaceutical Design, 2020, 26, 5547-5550.	0.9	0
923	Peripheral Arterial Disease and Emerging Biochemical Vascular Risk Factors. , 2007, , 111-116.		0
924	Lipids and Peripheral Arterial Disease. , 2007, , 35-40.		0
925	Re: biomedical publications profile and trends in gulf cooperation council countries. Sultan Qaboos University Medical Journal, 2012, 12, 378-9.	0.3	0
926	Carotid Artery Pathology in Inflammatory Diseases. American Journal of the Medical Sciences, 2021, , .	0.4	0
927	C-reactive protein-albumin ratio and erectile dysfunction. Andrologia, 2022, , e14386.	1.0	0
928	Optimal Management of Asymptomatic Carotid Stenosis: Counterbalancing the Benefits with the Potential Risks. Journal of Stroke, 2022, 24, 163-165.	1.4	0
929	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101842.	0.7	0